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The Impact of Third Year Pharmacy Students Providing Medication 
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Supervisor:  Jamie C. Barner 
 
This retrospective study was conducted to examine the impact of third-year 
pharmacy students’ provision of medication therapy management (MTM) on medication 
and health-related outcomes of patients in community pharmacies. The study objectives 
were as follows: 1) describe patients’ socio-demographic and clinical characteristics; 2) 
describe the number and types of medication and health-related problems (MHRPs) 
identified by students, as well as students’ MTM interventions and recommendations; 3) 
describe medical provider/patient MTM recommendation acceptance rates; and 4) 
determine which factors (i.e., baseline MHRPs, medical conditions, prescription 
medications, over-the-counter (OTC) medications and herbal supplements, number of 
medical prescribers, MTM interventions, and MTM recommendations) were related to 
the number of MHRPs resolved. 
The study used data (MTM cases) from a required MTM course, taught at The 
University of Texas at Austin College of Pharmacy. The study included MTM cases 
 vii 
provided by third-year pharmacy students enrolled in the Fall 2011 semester. MTM cases 
that were complete, unduplicated, and had patients aged ≥ 18 years were included the 
study. Descriptive statistics were used to address the first three study objectives. 
Multivariate linear regression was used to determine which factors were related to the 
number of MHRPs resolved.  
Out of the total number of MTM cases, 274 met the study inclusion criteria and 
served as the study’s final sample. The patients’ average age was 63.8 (±14.5), and the 
majority were female (60.4%) and Caucasian (53.2%). Almost one-third of the patients 
(30.7%) drank alcohol. The mean number of medical conditions and prescription 
medications was 6.0 (±2.7) and 9.0 (±4.0), respectively. Pharmacy students identified 
1,370 MHRPs [935 medication-related problems (MRPs) and 435 health-related 
problems (HRPs)] and recommended 1,004 medication and health-related 
recommendations (MHRRs) [542 medication-related recommendations and 462 health-
related recommendations]. Medical providers and/or patients accepted recommendations 
regarding drug discontinuation (34.8%) and OTC and herbal supplements (28.9%) at 
higher rates than other recommendations. Regarding the regression, the overall model 
was statistically significant, F=76.88, df=7, 240, p<0.001, and baseline MHRPs 
(β=0.127, t=2.09, p=0.04) and MTM recommendations (β =0.715, t=11.37, p<0.0001) 
were significantly related to MHRPs resolved.  
In conclusion, pharmacy students had a positive impact on patients’ medication 
and health-related outcomes through identifying MHRPs and providing MTM 
recommendations. The significant positive relationship between the number of MTM 
 viii 
recommendations and MHRPs resolved should encourage pharmacists and pharmacy 
students to be more eager to provide MTM recommendations, given the evidence that 
they will lead to improving patients’ medication and health-related outcomes. 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
1.1 INTRODUCTION 
Medication therapy management (MTM) is one aspect of the Medicare Modernization 
Act of 2003 (MMA), which was enacted by the US Congress.
1
 The Act required Medicare to not 
only pay for prescription medications, but also MTM.
1
 MTM is “a distinct service or group of 
services that optimize therapeutic outcomes for individual patients. MTM is independent of, but 
can occur in conjunction with, the provision of a medication product.”
2
 The MMA stated the 
three goals of MTM as follows: (1) to educate patients regarding medications; (2) to improve 
patients’ adherence to medication; and (3) to detect adverse drug reactions and patterns of 
incorrect prescription medication use.
3
 Providing MTM services was not limited to specific 
providers; however, pharmacists were the only healthcare professionals named as a provider of 
MTM services. According to the Center of Medicare and Medicaid Services, 96 percent of 
Medicare Part D MTM programs use pharmacists to provide MTM services.
4
 
Pharmacists-provided MTM services have improved the clinical and the economic 
outcomes of both patients and the health care system. From the clinical perspective, pharmacists 
identified and resolved many medication-related problems (MRPs)
5-15
 and they educated patients 
regarding their medications and health in general.
16
 In addition to having a clinical impact, 
pharmacists’ provision of MTM services also had an economic impact by saving patients money 
(e.g., by substituting lower priced medications for higher priced ones) and avoiding additional 
health care expenditures (e.g., emergency room visits).
17,18
 Pharmacists-provided MTM services 
indirectly saved patients and society the costs of missed or unproductive workdays.
17
 Patients 
were also satisfied with the MTM services that were provided by pharmacists. In two different 
 2 
studies, researchers found over periods of 2 and 10 years, respectively, that more than 95 percent 
of patients were satisfied with the MTM services that they received.
5,15
   
On the other hand, pharmacists also faced barriers when providing MTM services. These 
barriers could be divided into difficulties unrelated to pharmacists and difficulties related to 
pharmacists. Pharmacy setting issues (e.g., inadequate documentation systems),
19
 negative 
attitudes of other healthcare providers toward pharmacist-provided MTM,
20-22
 and a low MTM 
reimbursement from Medicare Part D could be classified as difficulties unrelated to 
pharmacists.
21,23
 In contrast, lack of specific MTM practice standards, lack of understanding 




Several strategies are available to remedy these difficulties. Barriers unrelated to 
pharmacists could be addressed by: (1) using advanced documentation and billing systems,
16
 (2) 
educating other healthcare providers about the impact of pharmacist-provided MTM services on 
patients’ overall health,
25
 and (3) adopting programs that compensate pharmacists for service 
provision.
26
 MTM provision barriers related to pharmacists might be remedied by completing 
training programs, such as “Delivering Medication Therapy Management Services in the 
Community,” which are designed to help pharmacists learn to provide MTM services 
effectively.
27
 Furthermore, pharmacy students can learn and practice providing MTM services, 
so that they are prepared to provide them in the future.
28,29
 
Several pharmacy colleges/schools of pharmacy have realized the importance of 
preparing their students to provide MTM. As a result, MTM courses have been proposed either 
as an entire course
30-32
 or as a part of a course,
33-41
 and they have been offered as a mandatory
34-
36,38-40
 or an elective course,
30,31,37,41,42
 usually for third-
31,32,35,36,38,39,42









 and MTM service provision to real or proxy patients.
30-32,36-38,41,43
 Patients 
who participate in MTM services have been general community pharmacy patients
37
 or specific 
types of patients (e.g., elderly, women, low-income, or uninsured patients).
30-34,42
 MTM course 
outcomes have focused on increasing students’ MTM knowledge and their abilities to provide 
MTM services, which include identifying and resolving patients’ MRPs and educating patients 
regarding their medication and overall health.
32,35-39,41
 MTM courses not only teach students how 
to provide MTM services to patients and increase their self-confidence in providing MTM, but 




A review of the literature revealed that student-provided MTM studies described: MTM 
course structure, students’ perceptions of the course and patient outcomes.
30-43
 However, none of 
the studies examined the impact of a required MTM course on community pharmacy patients’ 
medication and health related outcomes in which all students received lectures and provided 
MTM services. The University of Texas at Austin College of Pharmacy (UT-COP) developed an 
MTM course which is a mandatory for all third-year pharmacy students. In this course, students 
receive lectures about MTM and they provide MTM services at community pharmacies under 
the supervision of pharmacy preceptors.  
This study will address the following objectives: 
1. To describe patients’ demographic characteristics (age, gender, race), social 
history (smoking, alcohol and caffeine consumption), and clinical characteristics 
(medical conditions, prescription medications, over-the-counter (OTC) 
medications and herbal supplements, and number of medical prescribers)  
 4 
2. To describe the number and type of medication and health-related problems 
(MHRPs), MTM interventions, and MTM recommendations. 
3. To describe medical provider/patient MTM recommendation acceptance rates. 
4. To determine what factors (baseline MHRPs, medical conditions, prescription 
medications, OTC medications and herbal supplements, MTM interventions, 
number of medical prescribers, and MTM recommendations) are related to the 
number of MHRPs resolved (change in MHRPs from baseline to follow-up). 
 
This study will contribute to the literature by describing student-pharmacist MTM 
interventions and showing their impact on patients in community pharmacies. In addition, the 
study may benefit other college/school of pharmacies (C/SOPs) that are considering adding an 
MTM course to their curricula.  
 5 
1.2 LITERATURE REVIEW 
1.2.1 Medication-Related Problems (MRPs) 
 
Medications are a key factor in treating and preventing most diseases. However, 
medications are also associated with problems due to proper (e.g., adverse medication reaction 
(AMR)) and improper use and cost. The following discussion will illustrate how these issues are 
associated with improper use of medications.   
1.2.1.1 MRPs Due to Improper Use 
Incorrect use of medications, one aspect of medication-related problems (MRPs), can 
cause morbidity and mortality for many patients.  An MRP is defined by the American Society 
of Health-System Pharmacists as “an event or circumstance involving medication therapy that 
actually or potentially interferes with an optimum outcome for a specific patient.”
44
 These 
problems can be divided into two types: intrinsic and extrinsic toxicity.
45
 Intrinsic toxicity, which 
is considered synonymous with an adverse medication reaction (AMR),
45
 occurs due to the 
interaction between a drug’s pharmacological, pharmaceutical, and chemical properties and a 
patient’s biosystem. An AMR is defined by the World Health Organization (WHO) as “any 
response to a drug which is noxious and unintended and which occurs at doses normally used in 
man for prophylaxis, diagnosis or therapy of disease, or for the modification of physiological 
function.”
46
 Consequently, AMRs are divided into two types of reactions, Type A and Type B.
45
 
Type A reactions occur as a result of a medication’s pharmacological as well as clinical 
effects.
45
 Fortunately, this type of reaction can be avoided when patients receive the correct 
amount of the medication.
45
 For example, acetaminophen can cause liver cirrhosis, which occurs 
due to the medication’s pharmacological effect. As a result, this side effect can be avoided if 
patients do not take more than the maximum daily dose of acetaminophen, especially with long-
 6 
term use. Type B reactions occur in medications which have established therapeutic efficacy, but 
may also cause severe problems (e.g., anaphylactic shock), in a small number of patients.
45
 
In addition to intrinsic toxicity, extrinsic toxicity occurs due to mishandling of 
medications by healthcare providers (e.g., physicians, pharmacists, nurses) and/or by patients, 
which leads to medication errors.
45
 A medication error is defined as “any preventable event that 
may cause or lead to inappropriate medication use or patient harm while the medication is in the 
control of the healthcare professional, patient, or consumer.”
47
 Although several classifications 
for medication errors exist in the literature, van den Bemt et al. divided them into four main 
classes: prescribing errors, transcription errors, dispensing errors, and administration errors.
45,48
 
Each of these types is described below.  
Prescribing errors refer to the errors that may be caused by a healthcare provider in 
selecting, prescribing, and monitoring the medication. It might occur when a healthcare provider 
makes a mistake in selecting the medication or dose.  Regarding prescribing, the literature 
indicates that there are 3 to 6 prescribing errors for every 100 prescriptions.
49
 Moreover, the 
failure of a healthcare provider to monitor medications is considered a medication error. 
Transcription errors typically arise between prescribing and dispensing medications. This may 
occur when pharmacists or nurses misinterpret prescription details from a prescriber. Dispensing 
errors occur during the dispensing process and can include dispensing wrong medications, 
wrong doses, wrong instructions, or dispensing medications to wrong patients. Studies found the 
rate of dispensing error ranged from 0.08 percent – 4.0 percent of medications dispensed.
50-52
 
Administration errors may be caused by healthcare providers or patients. Similar to dispensing 
errors, healthcare providers may administer wrong medications, doses, or dosage forms, or use 
incorrect administration techniques. Bates et al. found 11 percent of adverse drug events 
 7 
occurred due to administration error.
53
 Patients may make administration errors when they take 
their medications at the wrong time or when they forget to take their medications. These patient 
errors can lead to medication non-adherence, which is defined as “the extent to which patients do 
not take medications as prescribed by their healthcare providers”.
54
 
1.2.1.2 MRPs Due to Cost 
 
In addition to MRPs due to improper use, there are problems associated with the costs of 
treating MRPs, which may require physician visits, emergency department visits, or additional 
medications. Previous research has indicated that adverse medication events cause up to 12 
percent of adult tertiary care emergency department visits.
55
 Estimating the cost of treating 
MRPs is difficult due to variations in cost-sharing responsibilities. However, the health care 
system pays a substantial amount of money for treating MRPs. In 1995, Johnson et al. estimated 
that drug-related morbidity and mortality costs were $76.6 billion in the ambulatory care setting 
in the United States,
56
 while in 2000, Ernst et al. estimated the cost at $177.4 billion.
57
 In 2007, 
an Institute of Medicine report estimated that 1.5 million adverse medication reactions (AMRs) 
occur annually, leading to 44,000 to 98,000 deaths every year in hospitals, with an associated 
loss of productivity. Moreover, the report showed that the additional medical cost for treating 
MRPs in hospital settings was approximately $3.5 billion per year, not including productivity 
loss.
58
 In conclusion, MRPs burden both health care systems and individual patients; thus, this 
issue needs to be addressed collaboratively with patients, healthcare providers, and health care 
systems.  
In addition to the cost of MRPs, the cost of medications themselves is also a burden to 
both patients and health care systems. In 2007, the cost of diabetes alone was approximately 
$174 billion, with direct medical costs totaling $116 billion.
59
 According to the U.S. census, 
 8 
increases in medication costs outpaced increases in overall health care expenditures from 2004 to 
2011.
60
 This increase impacts patients, because many have to pay a co-insurance, which is 
dependent on the cost of the medication. Increasing medication costs, especially medications for 
chronic disease, compel patients (e.g., low-income patients) not to adhere to their medications, 
which worsens their health status. Research indicates that low-income uninsured women are 
seven times more likely to face a cost barrier to prescription drugs, compared with higher income 
women with insurance.
61
 Appropriate medication management may be beneficial in reducing 
MRPs and enhancing patient outcomes. One specific method to address MRPs is medication 
therapy management (MTM), which is described below. 
1.2.2 Medication Therapy Management (MTM) 
 
In 2003, the Medicare Modernization Act (MMA) of 2003 required Medicare to not only 
reimburse the cost of prescription medications, but also the costs associated with managing these 
medications.
1
 This legislation, enacted in 2006, established the concept of Medication Therapy 
Management (MTM), which was associated with establishing Medicare Part D.
2
 Medicare Part D 
is a federal health insurance program that covers prescription medications of U.S. patients, who 
are: 1) age 65 or older; 2) under age 65 with certain disability; or 3) at any age with end stage 
renal failure.
62
 The 2011 eligibility criteria for Medicare Part D MTM enrollment is as follows: 
patients must have multiple chronic diseases, take multiple Part D drugs, and be likely to exceed 
$3,000 in annual medication costs.
4
  
The legislative language regarding MTM was purposefully broad to allow for 
competition among health plans.
3 
To assist pharmacists with implementation of MTM, the 
American Pharmacists Association (APhA) and the National Association of Chain Drug Stores 
(NACDS) developed a framework for MTM consisting of five core components: (1) Medication 
 9 
Therapy Review (MTR); (2) Personal Medication Record (PMR); (3) Medication Action Plan 
(MAP); (4) Intervention and Referral; and (5) Documentation and Follow-up.
63
 Providing MTM 
was not assigned to specific medical providers; however, pharmacists were named as healthcare 
professionals qualified to provide the service. In 2011, the Center for Medicare and Medicaid 
Services (CMS) reported that more than 96 percent of Medicare Part D MTM programs used 
pharmacists to provide MTM services.
4
 Following is a brief description of the five core MTM 
components. 
In Medication Therapy Review (MTR), the pharmacist reviews all patient medications, 
including: prescription medications, over-the-counter medications, herbal supplements, and 
immunizations. Also, this step requires the pharmacist to: (1) assess the patient’s cultural issues, 
language barriers, education level, and communication ability; (2) interpret and monitor the 
patient’s laboratory results; (3) identify the patient’s MRPs; (4) develop a plan for resolving each 
MRP; and (5) contact other healthcare professionals to solve the MRPs.
63
 
The next step is the creation of a Personal Medication Record (PMR), which is usually 
created electronically either by a pharmacist alone or in collaboration with the patient. It 
includes, but is not necessarily limited to, the primary physician’s name, the pharmacy and 
pharmacist’s names, the patient’s allergies, the patient’s MRPs, and medication information 
(name, dose, indication, instructions for use, start date, and stop date).
63
 
The pharmacist also creates a Medication Action Plan (MAP), which depends on the 
patient’s MRPs or recommendations. The MAP includes the patient’s name, primary care 
physician, pharmacy and pharmacist’s names, date of MAP creation, action steps for the patient, 
notes for the patient, and appointment information for follow-up with the pharmacist.
63
 
Importantly, this MAP includes only items that occur within a pharmacist’s scope of practice or 
 10 
that another medical provider has approved. Moreover, pharmacists should provide patients with 
a copy of the MAP and encourage them to share it with other healthcare providers.
63
  
Next, interventions and referrals may occur depending on the patient’s specific MRPs 
and condition. Interventions may involve the pharmacist working directly with the patient or 
with other healthcare providers. Moreover, a pharmacist may refer a patient to other healthcare 
providers, including pharmacists, who have more training and experience. Successful resolution 




Finally, pharmacists should document service provision and follow-up with the patient 
and/or another healthcare provider. This step allows a pharmacist to evaluate patient progress 
and it also facilitates communication between the pharmacist and other healthcare providers. 
Documentation helps pharmacists demonstrate the value of service provision, which is 
instrumental in obtaining payment for services. Lastly, pharmacists’ documentation of service 
provision may help protect against professional liability.
63
 
1.2.2.1 Impact of Pharmacist-Provided MTM on Outcomes 
Improving clinical outcomes is emphasized by Medicare regarding MTM service 
provision.
3
 In addition, providing MTM services has resulted in cost savings for the U.S. health 
care system.
5,14,15,17,18
 Pharmacists have identified and resolved MRPs and they have helped 
patients lower medication costs. Patient satisfaction is also an important MTM outcome.
5,13,15,64
 
The following describes clinical, economic, and satisfaction outcomes resulting from pharmacist 
provision of MTM. 
1.2.2.1.1 Clinical Impact 
 
 11 
Pharmacists have identified and resolved unnecessary drug therapy, improper drug 
selection, inappropriate dosing, drug-drug interactions, adverse drug reactions and poor 
medication adherence.
7-15
 Resolution of MRPs varies from study to study, but range from 45 to 
69.1 percent.
6,7,12,15
 One study noted that almost one-quarter (24.7%) of MRPs were resolved 
through education and counseling, whereas the remaining interventions required a change in 
patients’ medication regimen.
8
 The most common MRPs identified by pharmacists have been:  
need to change to a less expensive medication (33.3%-85%),
7,10,12
 need additional drug therapy 
(22%-39.8%),
6,8,14,15
 dosage too low (19.9%-26.1%),
14,15





 One study showed that interventions related to cost 
savings were most often approved by prescribers.
12
 In a study by Barnett et al., which examined 
pharmacists’ provided MTM from 2000-2006, the authors reported that pharmacists averaged 3.2 
MTM interventions per patient, with patient education/monitoring as the most common action 
(85.6%).
16
 Another study examined MTM provision between 1998 and 2008 and found that 
pharmacists provided 38,631 MRPs, of which the most common action was additional 
medication needed.
15
 In a study of MTM service provision via telephone, patients who received 
the services (i.e., intervention group) compared to the control group had significantly more 
medication and health-related problems resolved.
10
 In addition to detecting and resolving MRPs, 
pharmacists improved patients’ medication, disease state and medical device knowledge. 
7
  
Regarding medication adherence, one study showed that the most common problems 
were that patients could not afford medications, did not understand directions, preferred not to 
take the medication, and forgot to take the medication.
15
 Previous research found that after one 
year of MTM provision, medication adherence for patients who enrolled in MTM were 
significantly higher than those who did not enroll.
5
 Moreover, Medicaid patients who voluntarily 
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participated in the MTM intervention group had significantly higher medication adherence and 
persistence than Medicaid patients who did not participate in the MTM program.
11
 In addition, 
statins, insulin, oral hypoglycemic agents, proton pump inhibitors, and angiotensin-converting-
enzyme inhibitors were the top five categories of medications associated with nonadherence.
15
 
Pharmacists have also focused on various disease states (e.g., hypertension, 
cardiovascular disorders, diabetes, asthma, and dyslipidemia) when providing MTM.
6,7,13,17,18
 
The following clinical outcomes resulting from pharmacist-provided MTM include: reduced 
A1c,
15
 decreased blood pressure,
15,18





 Moreover, previous research indicates that chronically ill patients who 
received MTM had lower mortality compared to those who did not.
65
 
1.2.2.1.2 Economic Impact 
 
Pharmacists have had an impact on cost savings when providing MTM. Interventions 
such as substituting lower cost medications for higher cost medications have resulted in 
substantial cost savings for both the patient and the health care system. MTM provision in the 
Asheville project resulted in $628 average cost savings per person per year for 
cardiovascular/cerebrovascular-related medical health plan expenditures.
18
 Another study 
showed that for 207 asthmatic patients, pharmacists were responsible for a direct cost savings 
that averaged $725 per patient per year, and indirect cost savings that averaged $1,230 per 
patient per year.
17
 Researchers found that pharmacists saved the health care system $2,913,815 
over the 10-year period, while the total cost of MTM provision was $2,258,302.
15
 Reduction in 
total prescriptions per patient per month for patients who enrolled in the MTM program was 
higher than for patients who declined to enroll.
5
 Previous research found that, from the third-
 13 




1.2.2.1.3 Patient Satisfaction 
 
Another important MTM outcome is patient satisfaction. Previous research using a 15-
item survey to assess MTM satisfaction found that the average satisfaction score (1 = strongly 
disagree to 5 = strongly agree) for patients was 4.0(±0.6).
64
 Moreover, in two studies with 2 and 
10 year duration of MTM provision, more than 95 percent of patients were satisfied with the 
services they received.
5,15
 In addition to face-to-face interactions, patients were satisfied with 
MTM services provided via telephone and videoconference.
5,13
 
1.2.2.2 MTM Barriers and Strategies 
 
Although research has shown positive outcomes with MTM, pharmacists still have 
difficulties in providing optimal MTM services. These difficulties can be either unrelated or 
related to pharmacists. The following section describes these issues, as well as strategies to 
address them. 
1.2.2.2.1 Barriers Unrelated to Pharmacists and Strategies to Address 
 
Barriers not directly related to pharmacists include those involving: (1) pharmacy 
settings,
19
 (2) other healthcare providers,
20-22
 and (3) third party payers (e.g., Medicare Part 
D).
21,23
 Compared to community independent pharmacy settings, community chain pharmacies 
generally have higher reimbursement rates, better documentation systems, and more space for 
providing MTM.
19
 However, previous research indicates that independent pharmacies tend to 
provide more MTM services than chain pharmacies.
66
 One strategy for addressing billing and 






. These platforms provide training modules, access to a national 
network of patients, and internet-based documentation and claims payment processing, as well as 
data reporting.
16
 Another barrier unrelated to pharmacists is other healthcare providers (e.g., 
physicians, nurses) who may have negative attitudes toward pharmacists and MTM service 
provision. In a study of 102 West Virginia physicians, Alkhateeb et al., found that 51.5 percent 
of respondents reported that they never or rarely had contact with a pharmacist regarding 
patients’ medications. Moreover, 60 percent of respondents either agreed or strongly agreed that 
they supported cooperatively working with pharmacists, whereas only 36 percent supported the 
provision of MTM by pharmacists. Physicians who had more years of experience and specialists 
(vs. primary care) were more negative regarding pharmacist provision of MTM.
20
 Another study 
indicated that physicians believed that they were more suitable than pharmacists in providing 
MTM services.
22
 In addition, due to low reimbursement rates for their primary care services, 
some physicians mentioned that they would like to provide MTM services for additional 
revenue.
22
 Several solutions have been suggested in the literature for improving physician 
attitudes. First, physicians should receive information about the value of MTM programs in 
enhancing their patients’ health status. Second, pharmacists must demonstrate to other healthcare 
providers their clinical ability to improve patients’ outcomes.
25
 Next, regarding physicians’ 
reimbursement concerns, pharmacists can suggest to physicians that pharmacist-provided MTM 
services may enhance the physicians’ reimbursement rate by making them (i.e., physicians) 
available to see more patients.
22
 Fourth, pharmacists can enhance their communication with 
healthcare providers regarding their role in identifying and resolving MRPs, which may improve 




The third party payer, specifically Medicare, for MTM presents another barrier. Although 
Medicare Part D plans named pharmacists as MTM providers, pharmacists have deemed the 
reimbursement rate as low. Based on the Lewin Group recommendation, pharmacists should be 
reimbursed for providing MTM at $2 to $3 per minute, or $120 to $180 per hour,
68
 which is 
higher than Medicare Part D’s rates of $30 to $50 per hour.
69
 One way of addressing the low 
reimbursement rate may be to adapt Minnesota’s approach. In 2006, Minnesota began a program 
that paid pharmacists for time spent, number of MRPs identified, and number of medical 
conditions addressed. This type of program, which might result in higher reimbursement rates, 
may encourage more pharmacists to provide MTM services.
26
  
1.2.2.2.2 Barriers Related to Pharmacists and Strategies to Address 
 
Barriers related to pharmacists are within the pharmacists’ control and may be more 
easily modifiable. Pharmacists who provide MTM or who have an interest in providing such 
services agreed that the following were barriers to providing MTM: lack of specific MTM 
service practice standards and lack of understanding of MTM services components.
24
 Further, 
pharmacists consider lack of availability of and access to MTM educational resources as barriers 
to providing MTM services.
24
 Of the MTM service components, pharmacists were less confident 
in their skills to create an action plan for their patients.
70
  
Because other healthcare providers (e.g., physicians and nurses) are eligible to provide 
MTM, pharmacists should make strides to remove these barriers. Most of these barriers related to 
pharmacists are concentrated in some lack of understanding of MTM programs and a lack of 
educational resources.
24
 To help pharmacists overcome these barriers, the American Pharmacists 
Association (APhA) offers a variety of training programs that aid pharmacists in providing 
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optimal patient care. Moreover, the APhA and the American Society of Consultant Pharmacists 
(ASCP) have developed a specific training program for providing MTM services called 
“Delivering Medication Therapy Management Services in the Community” (DMTMSC). The 
DMTMSC enhances pharmacists’ clinical skills in assessing complicated medication regimens, 
identifying MRPs, and providing recommendations to patients, caregivers, and healthcare 
professionals. In addition, participants have resources to aid them in providing MTM, and 
participants who are APhA members have access to an MTM e-community for enhancing their 
MTM services.
27
 This type of program, along with other programs, such as Pharmaceutical Care 
for Diabetic Patients, may enhance pharmacists’ confidence, knowledge, and skills in providing 
optimal MTM services. 
Not only should pharmacists be educated and trained to provide MTM, but pharmacy 
students would also benefit from this as well since it may increase their ability and confidence in 
providing MTM in the future. The literature indicates that student pharmacists who practice 
providing patient care services in pharmacy schools tend to be more efficient in providing the 
same services in their pharmacy settings.
71
 For example, student pharmacists who had completed 
a diabetes concentration course in their pharmacy schools showed more ability and higher 
confidence in providing care to diabetics than pharmacists who had not.
71
 Therefore, pharmacy 
schools should be eager to educate their students on MTM provision.
72
 
1.2.3 MTM Curricula in Colleges/Schools of Pharmacy (C/SOPs) and Outcomes 
 
Training and preparing pharmacy students to provide MTM in the future may help 
diminish the gap between optimal MTM and current MTM service provision. Furthermore, it 
may provide pharmacy students with the experience and the confidence needed to provide MTM 
in their future pharmacy settings.
28,29
 The following section discusses MTM courses, specifically 
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prevalence, type, outcomes, barriers, and evaluation, as well as the impact of MTM courses on 
students’ perceptions regarding future practice.   
1.2.3.1 Prevalence of MTM Courses  
 
Available literature shows that several C/SOPs in the U.S. offer curricula on MTM 
service provision.
30-42
 Because of the differences in the types of MTM courses provided, the 
following terms are used to describe the prevalence of MTM courses: entire course
30-32







  (Note: Rovers et al. and Agness et al. 
studies did not include whether the MTM courses were elective or required.
32,33
) Based on the 
literature, the courses most likely to include MTM instruction were Pharmacotherapy 
Laboratory,
35,36,38,39
 Advanced Pharmacy Practice Experience,
33,34,37,40,41
 and Introductory 
Pharmacy Practice Experience.
32
 In addition, pharmacy students participated in courses that 





 years. However, for elective courses, a combination of 
students in different professional years were enrolled.
30
  
1.2.3.2 Description of MTM Courses in C/SOPs  
Pharmacy schools teach and/or train students to provide MTM services using different 
formats, such as: didactic lectures, case studies, proxy or real patients. Didactic lectures typically 
include information regarding the MTM framework and guidelines on how to identify and 
resolve MRPs, as well as how to review patients’ medications.
31,36,38,39
 A second teaching 
method is case study analysis,
31,36,38,39
 which often occurs after didactic lectures. This method of 
teaching is typically incorporated in laboratory courses where students are divided into 
subgroups to analyze the cases.
35,38,39
 The last type of MTM instruction involves allowing 
students to provide MTM services to proxy or real patients, which may be particularly effective 
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in helping students master service provision.
36
 The students provide MTM services (to proxy or 




 Pharmacy faculty members 
may act as mock patients and receive MTM to evaluate how students are providing the service.
38
 














patients at outpatient clinics,
42
 and community pharmacy patients.
37
 Not all students are able to 
provide MTM services due to the lack of MTM service provision in some community 
pharmacies.
37
 Moreover, some C/SOPs combine several methods to teach MTM, such as: MTM 
lectures with proxy or real patients.
31,32,36-38,41
 Some C/SOPs, however, use one only one teaching 
method (e.g., case studies, proxy/real patients) under the assumption that students have already 
had didactic lectures on the topic.
31,33-35,39,41
 Also, other C/SOPs have used documentation 
software, such as MirixaPro,® or the Tool to Improve Medications in the Elderly via Review 
(TIMER), to help students understand and provide MTM services to patients.
35,38
 
1.2.3.3 MTM Course Outcomes 
 
MTM outcomes assessed were dependent on the course objectives, which included 
increasing:  MTM knowledge;36,39 provision of medication and general health 
interventions35,36,38, provision of medication and health education;41 and identification 
and/or resolution of MRPs.32,36,37,41 Additional course objectives included assessing: the 
impact of using MTM documentation tools on students’ provision of MTM services;38 the 
correlation between students’ and clinical pharmacists’ interventions;33 and the impact of 
an MTM course on the students’ intentions to provide MTM services in the future.31,37,39 In 
one study, students’ MTM knowledge and ability to provide MTM services were measured 
after receiving an MTM lecture. As a result, almost two-thirds (64.7%) of students agreed 
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or strongly agreed regarding their enhanced ability to evaluate patients’ medications and 
analyze their safety and effectiveness; while, 93 percent of students were neutral to 
strongly disagree regarding their ability to document MTM services.36 Moreover, patients 
stated that both their medication understanding and health conditions were improved by 
student-provided MTM services.34,36,37 The literature indicated that students were able to 
detect 0.9 to 2.0 MRPs per patient32,34,36,37,42 and one medical problem per patient.32 The 
type of interventions by students were as follows: adding medication for an untreated 
indication (7% to 30%),37,41,42 optimizing the dose of a current medication (9% to 
24%),32,37,41,42 detecting medication nonadherence (12% to 50%),32,33,42 adding a 
medication for a new untreated indication (13% to 18.5%),32,41 changing a current 
medication to a more appropriate medication (18.5%),41 detecting adverse drug reactions 
(13% to 21.0%),33,37 discontinuing a medication without an indication (7% to 25%),32,33,41 
detecting a drug-drug interaction (15%),37 changing a drug due to cost (6% to 20%),37,42 
and changing the route of administration (4%).41  
Resolution of MRPs also resulted from students’ provision of MTM services. This 
was measured by examining the percentage of students’ interventions and 
recommendations that were accepted by patients’ healthcare providers. The literature 
indicated that 53 percent to 75 percent of such interventions were accepted by 
physicians.34,37,41 Similarly, in assessing the agreement between students and clinical 
pharmacists in identifying MRPs, clinical pharmacists agreed with 3 out of 7 medications 
that students identified as a MRP.33 Also, the literature indicated that students’ confidence 
in providing MTM services significantly (p<0.001) increased after providing MTM 
services.36 In another study, the majority of students [96% (2009), 79% (2010)] were 
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prepared to provide MTM in the future.37 Moreover, an MTM course compared students’ 
MTM perceptions of and intentions to provide MTM services in the future before and after 
providing MTM services to patients. The authors found that after providing MTM services, 
students’ perceptions were improved (pre-to post-MTM) with the following: intentions to 
provide MTM services (66.7% to 88.9%, respectively; p = 0.046),31 self-perceived 
pharmacy care skills (74.7% to 78.3%, respectively; p = 0.028),30 and in general ability to 
provide various aspects of MTM services (scale: 1=strongly disagree; 5=strongly agree; 2.5-
4.3 to 4.1-4.6, respectively; p < 0.006).36 In another study, the authors stated that 
integrating tools in MTM courses, such as MirixaPro® helped students understand MTM 
and increased their confidence in providing MTM services in their future setting.38 Using 
TIMER also resulted in significantly (p = 0.02) higher MRPs identified by students.35 
1.2.3.4 Barriers to Providing MTM Courses 
 
Attempts to establish MTM courses in C/SOPs have been limited due to clinical 
faculty funding, clinic or community pharmacy acceptance, and faculty expertise.40 Also, 
students reported that recruiting patients, scheduling the first visit and traveling off 
campus to provide MTM were the most common difficulties faced in providing MTM 
services.32 
1.2.3.5 MTM Course Evaluation and Student Perceptions 
 
After providing MTM services to patients, receiving didactic MTM training, and/or 
analyzing cases, several C/SOPs surveyed students to learn about their perceptions. The literature 
indicates that students valued the course for increasing their medication knowledge, interpersonal 
skills and professionalism.
54,60




 and they intended to provide MTM services in the future.
31
 In one study, 
20 out of 32 (62.5%) patients indicated that MTM services provided by students improved their 
medication knowledge and all of the patients (n=32) responded that they would recommend the 
students’ services to their friends and family.
34
 In addition to course evaluations, researchers 
have assessed students’ knowledge and intentions (using the Theory of Planned Behavior) to 
provide MTM services in the future.
63
 This type of assessment may reflect the overall impact of 
C/SOP’s curricula in preparing a new generation of pharmacists to provide MTM services. The 
researchers showed that most students agreed that MTM courses increased their knowledge of 
(range 94%-96%) and intention to (range 60%-67%) provide MTM services in the future.
37,73
  
1.2.4 The University of Texas at Austin at College of Pharmacy MTM Course  
 
At The University of Texas at Austin College of Pharmacy (UT-COP), an MTM course 
was developed as a pilot in 2010 and was subsequently offered as a required course for all third-
year pharmacy students (P3s), starting Fall 2011, to all campuses. This course, “Clinical Skills: 
Community Care,” was developed to train pharmacist-interns in MTM provision in community 
pharmacy practice (see Appendices A1 and A2 for the 2010 (pilot) and 2011 course syllabi, 
respectively). The course objectives were:  
“(1) Pharmacist-interns will be able to integrate basic clinical and scientific knowledge in the 
care of ambulatory patients in actual practice settings through the performance of Medication 
Therapy Management; (2) Pharmacist-interns will review patient medication histories and 
develop action plans to optimize a patient’s medication therapy and outcomes; (3) Educate 
patients on health and wellness through the development and execution of a public health project; 
(4) Assess patient safety by performing drug utilization reviews and drug information requests; 
and (5) Demonstrate longitudinal learning through continued application of patient assessment 
and immunizations.”  
 
Students are assigned to preceptors in community practice settings and must provide and 
document complete MTM services for five patients.  In addition, students are involved with 
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public health promotion and patient safety exercises. Additional course components will be 
explained in more detail in the Methods chapter. 
1.2.5 Summary 
 
C/SOPs responded to the demand of educating students regarding MTM. 
Consequently, the literature showed that C/SOPs provided MTM courses using a variety of 
formats such as: having an entire course or part of a course; offering the course as required 
or elective; using teaching formats such as didactic, case studies, proxy/real patients and 
combinations of the aforementioned. However, none of the studies in the literature 
described the impact of a required ‘entire’ MTM course in which all students completed a 
training program, received lectures, and provided services to patients in community 
pharmacies. Examining the impact of the UT-COP MTM course on student and patient 
outcomes may benefit other C/SOPs that are considering adding or revising MTM courses 
in their curricula. Below is a description of the study objectives and hypotheses.  
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1.2.6 Objectives and Hypotheses  
1. To describe patients’ demographic characteristics (age, gender, race), social history 
(smoking, alcohol and caffeine consumption), and clinical characteristics (medical 
conditions, prescription medications, over-the-counter (OTC) medications and herbal 
supplements, and number of medical prescribers)  
2. To describe the number and type of medication and health-related problems (MHRPs), 
MTM interventions, and MTM recommendations. 
3. To describe medical provider/patient MTM recommendation acceptance rates. 
4. To determine what factors (baseline MHRPs, medical conditions, prescription 
medications, OTC medications and herbal supplements, MTM interventions, number of 
medical prescribers, and MTM recommendations) are related to the number of MHRPs 
resolved (change in MHRPs from baseline to follow-up). 
H1:  The number of baseline MHRPs will be positively and significantly related to 
the number of MHRPs resolved while controlling for other factors. 
H2:  The number of medical conditions will be positively and significantly related 
to the number of MHRPs resolved while controlling for other factors.  
H3:  The number of prescription medications will be positively and significantly 
related to the number of MHRPs resolved while controlling for other factors. 
H4: The number of OTC medications and herbal supplements will be positively and 
significantly related to the number of MHRPs resolved while controlling for 
other factors. 
H5:   The number of MTM interventions will be positively and significantly related 
to the number of MHRPs resolved while controlling for other factors. 
H6: The number of medical prescribers will be positively and significantly related 
to the number of MHRPs resolved while controlling for other factors. 
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H7:   The number of MTM recommendations will be positively and significantly 











CHAPTER TWO: METHODOLOGY 
This chapter describes the methodology used to conduct the present study. It provides 
information about the study setting and the data source, inclusion criteria, and a description of 
the study intervention. In addition, the study’s dependent and independent variables and the 
statistical tests used are presented. 
2.1 STUDY SETTING, INCLUSION CRITERIA AND DATA SOURCE 
This is a retrospective study using data from an academic course, Clinical Skills: 
Community Care, taught at The University of Texas College of Pharmacy (UT-COP). The 
course was established to help students: (1) integrate clinical and scientific knowledge through 
providing MTM, (2) review patients’ personal medications and create an action plan to maximize 
the patients’ medication outcomes, (3) educate patients on health through the development of 
public health projects, and (4) evaluate patients’ safety by performing a drug utilization review. 
The course is mandatory for all third-year pharmacy students. Because of the large number of 
third-year students (121 third-year students), the course was first offered as a mandatory course 
to 67 students in the Fall 2011 semester, and then to 54 students in the Spring 2012 semester. 
The present study focuses on the Fall 2011 semester. Moreover, the course was offered at four 
different campuses (UT Austin, UT Health Science Center San Antonio, UT El Paso, and UT 
Pan-America).  All third-year (P3) Fall 2011 students (on all four UT campuses) who were 
enrolled in the course were included in the study. As mentioned previously, students were 
required to complete five patient cases.  All adult (≥18) completed, non-duplicative patient cases 
served as the study population. 
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2.2 INSTITUTIONAL REVIEW BOARD APPROVAL 
The University of Texas at Austin Institutional Review Board approved the study. 
Moreover, because the data were de-identified (patients’ and students’ names were removed 
from the forms), the threat to privacy is minimal.  
2.3 COURSE DESCRIPTION  
2.3.1 Course Syllabus  
 
The MTM course, PHR 287H - Clinical Skills: Community Care, was developed, 
coordinated, and taught by Professor Sharon Rush. The purpose of the course was to aid 
pharmacy students in understanding the profession of pharmacy from a community pharmacy 
perspective and to prepare pharmacist-interns for their Advanced Pharmacy Practice Experience 
in their fourth professional year.  
The course objectives were to help pharmacist-interns incorporate basic clinical skills in 
the care of ambulatory patients in real practice settings, to evaluate and optimize patients’ 
medication therapies and outcomes, to develop public health projects to educate patients on 
health and wellness, to implement drug utilization review and drug information requests to 
determine patient safety, to perform patient assessments and to administer immunizations. See 
Appendix A2 for the course syllabus. 
The primary prerequisite for the course was having completing the second professional 
year in the College of Pharmacy. P3 students were assigned to a preceptor and required to 
participate in community/ambulatory care-specific activities. Completion of 80 experiential 
hours at approximately 4-6 hours per week was required. All students were required to 
participate in activities related to the following: (1) Medication Therapy Management, which 
included completing the national certificate of the American Pharmacists Association’s 
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(APhA’s) “Delivering Medication Therapy Management Services in the Community” and 
completing five comprehensive Medication Review MTM cases; (2) public health promotion, 
which included activities to improve the health and wellbeing of patients; (3) patient safety 
exercises, which included completing one drug utilization review, one drug information request, 
and one medication calendar for an MTM patient; (4) reflections on experiences, which required 
the students to report weekly on what they learned; and (5) any two of the following elective 
activities: administration of immunizations, demonstration of patient assessment skills (e.g., 
health screenings), or other requested by the preceptor. In addition, students were encouraged to 
read literature, such as “Medication Therapy Management on Pharmacy Practice: Core Elements 
of an MTM Services Model” – version 2.0, Motivational Interviewing, as well as other handouts 
assigned by the instructor. All the required documentation, such as MTM forms, public health 
forms, patient safety forms, and electives forms, were placed on Blackboard, a web-based course 
management system, which allowed the students to access the documents. 
A student’s schedule in his or her assigned practice was determined by both the preceptor 
and the student. Moreover, the student, the preceptor, and the practice site determined the 
number of hours scheduled each week, which might include working at night or weekends. 
Students’ hours at their practice site had to be divided approximately as follows: 70 percent for 
MTM, 15 percent for public health, 5 percent for patient safety, and 10 percent for elective 
experiences. All students were also required to abide by all the pharmacy sites’ rules and 
regulations.  
2.3.2 MTM Form  
 
The MTM form (Appendix A3) was used by students in the provision and documentation 
of MTM services. It was divided into five sections: (1) Medication Therapy Review, (2) 
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Pharmacist Action Plan, (3) Pharmacist Action Plan Progress Notes, (4) Patient Medication 
Record, and (5) Patient Medication Action Plan. The following describes each section.  
2.3.2.1 Medication Therapy Review (MTR) 
 
The Medication Therapy Review section was formatted based on the information 
supplied to the student by the patient. This section was to remain in the patient’s file at the 
practice setting to be used as a reference in communicating with the patient’s other healthcare 
providers. In addition to the student’s name, the date prepared, and the practice setting’s name 
and phone number, this section included the patients’ name, year of birth, race, sex, height, 
weight, blood pressure, and blood glucose. The students also documented the reason that brought 
the patient to receive MTM services, whether a comprehensive review or a targeted visit (e.g., 
checking on a particular health problem or concern) was needed. The student documented any 
question the patient might have about his or her medication or disease or condition. This section 
included type, duration and frequency of smoking, alcohol and caffeine use. Medication allergies 
and adverse medication reactions, as well as medical conditions, such as alcoholism, 
breastfeeding, depression, heart failure, obesity, and others, were included in this section. Next, 
the student documented all medication-related information for prescription medications, over-
the-counter medications, and herbal supplements, which included name, dose, directions, 
indications, prescribing physician, and comments. This information was to help the student 
understand what medications and supplements the patient used, how the patient used them, and 
what information the patient knew about them. Also, the student recorded patient immunization 
status. In conclusion, this section was necessary to students in providing MTM services because 
it provided important information to help students identify and resolve MRPs. 
 29 
2.3.2.2 Pharmacist Action Plan (PAP) 
 
After reviewing the patient’s personal medication therapy, the student created the 
Pharmacist Action Plan (PAP). The PAP documented the MRPs, the priority level (i.e., high, 
medium, and low) of these problems, and the intervention proposed to resolve each particular 
problem. Moreover, the student was to document if he or she had advised the patient to follow up 
with other healthcare providers, as well as the outcomes that resulted from identifying MRPs. 
Also, the students were to indicate whether they provided a copy of the PMR and MAP to the 
patient, made a referral to other healthcare providers, and to whom they had referred the patient. 
2.3.2.3 Pharmacist Action Plan Progress Notes 
 
This section was used to document student interventions and whether s/he followed up 
with the patient. This was used as a summary for the MTM service and as a measurement of the 
overall effectiveness of the MTM service. It also enabled effective communication between 
pharmacy staffs and students concerning the progress of the case.    
2.3.2.4 Patient Medication Record (PMR) 
 
In this section, students recorded all patient medications and herbal supplements on a 
Patient Medication Record (PMR), and they advised patients to carry it with them to share with 
other healthcare providers. The information included names of all medications and supplements, 
doses, indications, prescriber names, dose times, and any special instructions.  
2.3.2.5 Patient Medication-Related Action Plan (MAP) 
 
After creating the PAP, the students provided patients with their own personal 
medication-related action plans (MAPs). In addition to the patient’s name and date of birth, as 
well as the name and the phone number of his or her primary physician and pharmacy, the 
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student had to provide the patient with the critical steps that would help him or her have optimal 
outcomes. The student also encouraged the patient to accomplish those steps with the patient’s 
other healthcare providers and to document what and when those steps were completed. 
2.4 STUDY VARIABLES  
Below is a description of the dependent and independent variables used in the study.  Table 
2.1 summarizes the variables and their operational definitions. 
2.4.1 Dependent Variables  
 
2.4.1.1 Medication and Health Related Problems (MHRPs) 
 
The MTM interventions captured more than MRPs, they also included disease 
management and preventive care problems.  Thus, the term Medication and Health Related 
Problems (MHRPs) will be used to represent the dependent variable. Patients’ MHRPs at 
baseline are the number of MHRPs that were identified by students during the first MTM visit.  
Similarly, patients’ MHRPs at follow-up were identified during the follow-up visit (if any). Prior 
to deidentification, patients’ baseline and follow-up visits were matched by using the following 
data: age, race, gender, primary physician’s name and phone number, and primary pharmacy’s 
name and phone number. A form, adapted from Moczygemba et al.,
74
 was created to document 
the number and type of MHRPs (See Appendix A4). After reviewing several documented student 
MTM forms, MHRP categories were added and/or modified to address the study objectives (see 
Appendix A5) and further detail below in Section 2.4.2.2. 
2.4.1.2 Resolution of MHRPs 
 
Resolution of MHRPs was calculated for patients who had follow-up visits and was 
identified by any change in the number of MHRPs from baseline to follow-up MTM visits (i.e., 
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Number of MHRPs baseline-Number of MHRPs follow-up). Patients who had a follow-up visit 
could be identified by matching their data as described above.  
2.4.1.3 Acceptance Rate of MTM recommendations 
 
At follow-up visits (if any), patients were asked to determine whether they/their 
healthcare providers accepted MTM recommendations. Acceptance rates were calculated for 
patients with follow-up visits as: Provider/patient MTM recommendations acceptance / Number 
of MTM recommendations made. 
2.4.2 Independent Variables  
 
2.4.2.1 Patient Demographics and Social History  
 
Demographic variables were age, gender, and race. Age was a continuous variable and 
represented the age of patients in years at the time of MTM services. Gender was a dichotomous 
variable and coded as 1 for male and 2 for female. Race was categorical and coded as 1 for 
White, 2 for African American, 3 for Hispanic, 4 for Asian, and 5 for other races. Social history 
included whether or not the patient smoked or drank alcohol (1 = Yes, 0 = No). 
2.4.2.2 Number and Type of MTM Interventions and Recommendations 
 
Students’ MTM interventions and recommendations were reviewed and classified into 
groups (see Appendix A5). Students’ interventions related to the identification of MHRPs were 
classified into eight categories, problems related to: (1) drug product selection; (2) drug regimen; 
(3) precautions, interactions, and contraindications; (4) adverse effects and use; (5) 
Immunization; (6) social history and life style issues; (7) lack of understanding drug indication 
and continuity of care; and (8) disease monitoring and control. Students’ interventions included 
actions such as contacting other healthcare providers, counseling patients/caregivers, which 
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included providing them with verbal or written instructions on taking the medications, educating 
patients, which included providing them with verbal or written instructions on overall health, or 
referring the patients to other healthcare providers. Likewise, students’ MTM recommendations 
were also classified into groups as follows: recommendations related to (1) medications, (2) 
preventive care, (3) immunizations, (4) diabetic, hypertensive, and dyslipidemic patients, and (5) 
smoking and alcohol use. 
2.4.2.3 Patients’ Clinical Characteristics 
 
The medical conditions were defined as the total number of disease(s) that patients had at 
the time of MTM services. The total number of patients’ prescription medications and total 
number of over-the-counter and herbal supplements used at the time of MTM services were 
documented. Walgreens Preferred Medication List — Medication Category Guide (see Appendix 
A6) was used to classify patients’ medications into categories. Lastly, the total number of 
medical prescribers was documented as well as the type of immunizations that patients obtained 










Table 2.1 Description of Study Variables 
Variable  Operational Definition 
DEPENDENT VARIABLES 
Medication and health related problems  Number of MHRPs at baseline and follow-up 
Medication and health related problems 
resolved 
Change in number of MHRPs from baseline to follow-up 
Acceptance rate of MTM recommendations Provider/patient MTM recommendations acceptance / Number of 
MTM recommendations 
INDEPENDENT VARIABLES 
Demographics and Social History  
Age  Age (years) at baseline 
Race 1 = White, 2 = African American, 3 = Hispanic, 4 = Asian, 5 = 
Others 
Gender  1 = Male, 2 = Female 
Smoking 0 = No, 1 = Yes 
Caffeine 0 = No, 1 = Yes 
Alcohol use 0 = No, 1 = Yes 
Clinical Characteristics  
Number and type of MTM interventions 
and recommendations  
(See Appendix A5) 
MTM interventions related to:  
(1) Drug product selection; (2) Drug regimen; (3) Precautions, 
contraindications, and interactions; (4) Adverse effects and use; (5) 
Immunization; (6) Social history and life style issues; (7) Lack of 
understanding drug indication and continuity of care; and (8) 
Disease monitoring and control. 
MTM recommendations related to: 
(1) Medications, (2) Preventive care, (3) Immunizations, (4) 
Diabetic, hypertensive, and dyslipidemic patients, and (5) Smoking 
and alcohol use  
Medical conditions  Total number of medical conditions at baseline  
Prescription medications Total number of prescription medications at baseline  
Over-the-counter medications and herbal 
supplements  
Total number of OTCs and herbal supplements at baseline 
Medical prescribers  Total number of medical prescribers at baseline 
Immunizations  Type of immunizations at baseline 
2.5 STATISTICAL ANALYSIS 
Several statistical analysis tests were used to address the study objectives. SAS version 
9.3 was used and a significance level of p < 0.05 was chosen. Table 2.2 describes the statistical 
analyses that were conducted to address the study objectives. Descriptive statistics (i.e., mean, 
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standard deviation, frequency) were used to address study objectives 1-3 and multiple linear 
regression was used to address objective 4. The following three assumptions must be met to 
conduct multiple regression: (1) independent observations; (2) normally distributed dependent 
variables; and (3) linearity between dependent and the independent variables. Because each 
student is providing MTM services independently, the first assumption is met.  Moreover, a 
histogram of the standardized residuals was used to check the assumption of normality, while 
residual plots were used to check for linearity.
75
 Following is the multiple regression equation 
that was used in the study.  
Y'=a+b1X1 +b2X2 +b3X3 +b4X4+b5X5+b6X6 +b7X7 
Following are the model variables:  
Y' = Change in the number of MHRPs from baseline to follow-up   
X1: Baseline MHRPs 
X2: Medical conditions  
X3: Prescription medications 
X4: OTC medications and herbal supplements 
X5: MTM interventions 
X6: Medical prescribers 
X7: MTM recommendations  
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Table 2.2: Data Analysis Plan  
OBJECTIVE 1: To describe patients’ demographic, Social History, and clinical characteristics  
Variables Measurement level  Analysis 
Age  Continuous  Descriptive 
statistics (e.g., 
mean, frequency) 
Gender Dichotomous  
Race Categorical  
Smoking  Dichotomous  
Alcohol use Dichotomous  
Caffeine use Dichotomous 
Medical conditions Continuous  
Prescription medications Continuous  
OTC and herbal supplements  Continuous 
Medical prescribers  Continuous 
Number of immunizations Continuous 
OBJECTIVE 2: To describe the number and type of medication and health related problems 
(MHRPs) and MTM interventions and recommendations 
Variables Measurement level  Analysis 
Number of MHRPs  Continuous  Descriptive 
statistics (e.g., 
mean, frequency) 
Type of MHRPs Categorical  
Number of MTM interventions Continuous  
Type of MTM interventions Categorical 
Number of MTM recommendations Continuous 
Type of MTM recommendations Categorical 
OBJECTIVE 3: To describe the medical provider/patient acceptance rate of MTM 
recommendations  
Variables Measurement level  Analysis 
Medical provider acceptance rate of 
the types of MTM recommendations  
Continuous  Descriptive 
statistics (i.e., 
mean)  
OBJECTIVE 4: To determine what factors are related to the number of MHRPs resolved  
DV Measurement 
level 
IV Measurement level Analysis 
MHRPs 
resolved 




OTC and herbal 
supplements 
MTM interventions 
Medical prescribers  
MTM 
recommendations 




2.6 SAMPLE SIZE ANALYSIS  
Calculating the needed sample size is important to ensure the adequacy of the study 
power and then avoid having a high Type II error, which lead to incorrectly accepting the null 
Hypothesis. In order to calculate the needed ample size, three components have to be 
determined. These components are: 1) the critical p-value, Alpha (  ; 2) study power; and 3) the 
study effect size. Prior to conduct the study, the three components were determined as following: 
Alpha (   equal to 0.05, power equal to 0.80; and a medium effect size (R2 = 0.13) based on 
conventional values.
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 Based on the formula in Figure 2.1 and seven independent variables,
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 , 








N = estimated sample size  
L = tabled value for the desired   and power 
K = number of predictors 
   = estimated effect size  
R
2 
= percent of variance explained by the model  
  
N= (L/ ) + k + 1        = effect size = R2/(1-R2) 
Figure 2.1 Formula for Calculating Multivariate Regression Sample Size 
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CHAPTER THREE: RESULTS 
 
This chapter includes the study results. The first section describes the study’s inclusion 
criteria and the total number of patient cases. Then, the patients’ demographics, social histories, 
and clinical characteristics are detailed. The next section describes the medication and health 
related problems (MHRPs), interventions, and recommendations that were identified and 
provided by pharmacist-interns. Following, the chapter describes the acceptance rate of 
pharmacist-interns’ recommendations, and lastly, the study hypotheses will be described. 
3.1 INCLUSION CRITERIA 
This study used the MTM cases that were documented by pharmacist-interns during the 
provision of MTM services. A total of 335 cases were documented as receiving MTM services. 
Sixty-one cases did not meet the inclusion criteria for the following reasons: patient <18 years 
(n=4); duplicated case (n=52); and incomplete documentation (n=5). The final total sample was 
274 patient cases. 
3.2 PATIENTS DEMOGRAPHICS, SOCIAL HISTORIES, AND CLINICAL CHARACTERISTICS 
Patient’s demographics, social histories, clinical characteristics are described below (see 
Tables 3.1 - 3.12).  
3.2.1 Patients’ Demographics 
Patients’ demographics, which included patients’ age, gender, and race, are detailed in 
tables 3.1-3.3. The patients’ average age was 63.8 (± 14.5), and the majority of patients were 55-
74 years old (52.5%) (see Table 3.1). Female patients accounted for 60.4 percent of total patients 
(see Table 3.2), and Caucasians accounted for 53.2 percent of patients, followed by Hispanics 
(37.8%) (see Table 3.3).  
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Table 3.1 Mean and Frequency Distribution of Age 
Age Number Percent (%) 
18-34 10 4.2 
35-44 15 6.4 
45-54 30 12.7 
55-64 60 25.4 
65-74 64 27.1 
75-84 44 18.6 





Mean age (SD): 63.8 (±14.5) 
a 
38 responses were missing. 
b 
Total does not equal 100 percent due to rounding.  
 
 
Table 3.2 Frequency Distribution of Gender  
Gender  Number  Percent (%) 
Male  108 39.6 









Table 3.3 Frequency Distribution of Race  
Race  Number  Percent (%) 
Caucasian   124 53.2 
Hispanic  88 37.8 
African American  13 5.6 









 Other included Indian and Iranian.  
b 
41 responses were missing.  
c 
Total does not equal 100 percent due to rounding. 
 
 39 
3.2.2 Patients’ Social History 
Patients’ social history included smoking cigarettes, drinking alcohol and caffeinated 
beverages. Almost two-thirds (65.2%) were caffeine drinkers, while almost one-third (30.7%) 
drank alcohol (see Table 3.4). 
 
Table 3.4 Frequency Distribution of Tobacco Smokers, Alcohol Beverage Drinkers, 
and Caffeine Beverages Drinkers 














7 responses were missing. 
b 
7 responses were missing. 
c
 21 responses were missing.  
 
3.2.3 Patients’ Clinical Characteristics 
Patients’ clinical characteristics included number and type of medical conditions, number 
and type of prescription medications, number and type of over-the-counter (OTC) medications 
and herbal supplements, number of medical prescribers, and number and type of immunizations. 
The average number of medical conditions was 6.0 ( 2.7), and the highest frequency of patients 
had 5-6 medical conditions (32.9%) (see Table 3.5). More than one-half of patients had 








Table 3.5 Mean and Frequency Distribution of Number of Medical Conditions  
Number of Medical 
Conditions  
Number  Percent (%) 
0 1 0.4 
1-2 16 5.8 
3-4 72 26.3 
5-6 90 32.9 
7-10 78 28.5 
11-15 17 6.2 
Total  274 100.1
a 
Mean number of medical conditions (SD):  6.0 (±2.7) 
a 
Total does not equal 100 percent due to rounding. 
 
Table 3.6 Top 10 Most Prevalent Medical Conditions  
Medical Condition  Number  Percent (%)  
Hypertension  221 80.7 
Dyslipidemia 186 67.9 
Diabetes 153 55.8 
Depression 110 40.2 
Arthritis  87 31.8 
Chronic pain 83 30.3 
Gastrointestinal disorder 77 28.1 
Thyroid disorder 72 26.3 
Obesity 57 20.8 
Heart disease  50 18.3 
 
The mean number of prescription medications was 9.2 (±4.0), and the highest frequency 
of patients (30.7%) had 7-9 prescription medications (see Table 3.7). The mean number of OTC 
medications was 2.2 (±2.0), and most (28.1%) were using one OTC medication (see Table 3.8).  
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Table 3.7 Mean and Frequency Distribution of Number of Prescription Medications  
Number of Prescription 
Medications 
Number  Percent (%) 
1-3 13 4.7 
4-6 59 21.5 
7-9 84 30.7 
10-12 75 27.4 
13 43 15.7 
Total  274 100.0
 




Table 3.8 Mean and Frequency Distribution of Number of Over-the-Counter (OTC) 
Medications  
Number of Over-the-Counter 
(OTC) Medications  
Number  Percent (%) 
0 52 19.0 
1 77 28.1 
2 46 16.8 
3 27 9.9 
4 39 14.2 
5 33 12.0 
Total  274 100.0
 
Mean number of over-the-counter medications (SD): 2.2 (±2.0) 
 
The Walgreens Preferred Medication List was used to classify medications based on their 
therapeutic categories. Over one-half of patients used medications classified as blood pressure 
agents (82.9%), analgesic agents (71.9%), cholesterol agents (67.2%), vitamins, minerals, or 
electrolytes (59.9%), and diabetic agents (54.0%), (see Table 3.9).  
The mean number of herbal supplements was 0.5 (±1.3), and the majority (81.0%) did not 




Table 3.9 Frequency Distribution of Medication Category 
Medication Type Number Percent (%) 
Blood pressure agents 227 82.9 
Analgesics 197 71.9 
Cholesterol agents 184 67.2 
Vitamins, minerals & electrolytes  164 59.9 
Diabetic agents 148 54.0 
Antidepressants 120 43.8 
Gastrointestinal agents 119 43.4 
Hormones 114 41.7 
Diuretics 89 32.5 
Anticonvulsants 73 26.6 
Anticoagulation therapies  63 23.0 
Antiasthmatics and COPD
a 
agents 62 22.6 
Cough, cold, and allergy agents 58 21.2 
Musculoskeletal agents 51 18.7 
Antianxiety agents 48 17.5 
Urologic agents 47 17.2 
Eye, ear, nose, and throat agents  46 16.8 
Sleep aids 45 16.4 
Anti-infectives 21 7.7 
Antipsychotics 21 7.7 
Heart rhythm stabilizers 17 6.2 
Alzheimer’s agents 10 3.7 
Antiparkinsonism agents 10 3.7 
Skin agents 8 3.0 
Migraine agents 5 1.8 
HIV
b
 agents  4 1.5 
Oncology agents 1 0.4 
Others 91 33.2 
a 
Chronic obstructive pulmonary disease 
b 




Table 3.10 Mean and Frequency Distribution of Number of Herbal Supplements  
Number of Herbal 
Supplements  
Number Percent (%) 
0 222 81.0 
1-2 31 11.3 
3 21 7.7 
Total  274 100.0 
Mean number of herbal supplements (SD): 0.5 (±1.3) 
 
The mean number of medical prescribers was 2.4 (±1.5), and the majority (62.8%) had 
one (31.1%) or two (30.7%) medical prescribers (see Table 3.11). Regarding immunizations, 
almost one-half of patients received the influenza (51.5%) and pneumococcal (50.0%) vaccines 
(see Table 3.12). 
 
Table 3.11 Mean and Frequency Distribution of Number of Medical Prescribers  
Number of Medical Prescribers  Number  Percent (%) 
1 77 31.1 
2 76 30.7 
3 47 19.0 
4 23 9.3 





Mean number of medical prescribers (SD): 2.4 (±1.5) 
a 
26 responses were missing.  
b 








Table 3.12 Frequency Distribution of Immunizations Type 
Type of Immunization
a



























3.3 IDENTIFICATION OF MEDICATION AND HEALTH-RELATED PROBLEMS (MHRPS) AND 
MTM INTERVENTIONS  
The core of this study, aside from MTM outcomes, is examining pharmacist-interns’ 
identification of patients’ medication and health related problems (MHRPs) and MTM 
interventions. To provide MTM services, pharmacist-interns were encouraged to meet patients 
face-to-face; however, due to conflicts, some pharmacy students provided MTM via telephone.  
3.3.1 Identification of MHRPs 
MHRPs were initially classified into problems related to medications, immunizations, 
social histories and lifestyle issues, lack of understanding drug indications and continuity of care, 
and disease monitoring and control. First, MHRPs were classified into problems related to (1) 
drug product selection; (2) drug regimen; (3) drug precautions/ interactions/contraindications; 
and (4) drug adverse effects and use (see Tables 3.13 – 3.16). Regarding problems related to 
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OTC medications and herbal supplement, pharmacist-interns were able to identify at least one 
problem in 20.4 percent of patients (see Table 3.13). The most commonly identified medication 
problems were OTC and herbal supplement use, cost/formulary interchange and duplication (see 
Table 3.13).  
 
Table 3.13 Frequency Distribution of Type of Problems Related to Drug Product 
Selection (N=274) 
Problem Number identified  N Percent (%) 
Over-the-counter 
(OTC) and herbal 
medications 
0 218 79.6 
1 44 16.0 
2 9 3.3 














0 235 85.8 
1 31 11.3 
2 5 1.9 
3 3 1.1 
 
 Duplication 0 235 85.8 
1 37 13.5 
2 2 0.7 
Drug safety 0 236 86.1 
1 33 12.0 
2 3 1.1 
3 2 0.7 
Drug needed but not 
prescribed 
0 239 87.2 
1 30 11.0 
2 2 0.7 
3 3 1.1 
Drug efficacy 0 243 88.7 
1 28 10.2 
2 3 1.1 
Prescribed drug not 
needed 
0 268 97.9 
1 5 1.8 
2 1 0.4 
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Table 3.14 shows the highest frequencies of problems related to drug regimen were 
medication dose, with at least one found in 14.6 percent of patients, followed by problems 
related to schedule/duration in 14.2 percent of patients. No problems were found related to route 
of administrations (see Table 3.14).  
 
Table 3.14 Frequency Distribution of Type of Problems Related to Drug Regimen 
(N=274) 
Problem Number Identified  N Percent (%) 
Dose 0 234 85.4 
1 36 13.1 
2 3 1.1 
3 1 0.4 
Schedule/duration 0 235 85.8 
1 27 9.9 
2 9 3.3 




0 263 96.0 
1 10 3.7 
2 1 0.6 
Dosage form 0 272 99.3 
1 2 0.7 
Route of 
administration  
0 247 100.0 
Other
a
 0 281 98.9 
1 3 1.1 
a 
Insulin injection site  
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Furthermore, for problems related to precaution/interaction/contraindication, the highest 
percentage of problems was found related to drug interaction, with at least one problem in 48.5 
percent of patients, and at least two problems in 22.3 percent of patients (see Table 3.15). 
Additionally, regarding problems related to adverse effects and use, 23.0 percent of patients had 
at least one problem related to additive effect, and 20.8 percent of patients were having at least 
one problem related to underuse (see Table 3.16). 
Table 3.15 Frequency Distribution of Type of Problems Related to 
Precautions/Interactions/Contraindications (N=274) 
Problem Number Identified  N Percent (%) 
Drug interaction  0 141 51.5 
1 72 26.3 
2 33 12.0 
3 12 4.4 
4 9 3.3 
5 6 2.2 
10 1 0.4 
Disease or condition 0 239 87.2 
1 26 9.5 
2 2 0.7 
3 6 2.2 
4 1 0.4 
Food 0 260 94.9 
1 12 4.4 
2 2 0.7 
Alcohol 0 263 96.0 
1 8 2.9 
2 1 0.4 
3 2 0.7 
Age 0 271 98.9 
1 3 1.1 
Laboratory 0 274 100.0 




Table 3.16 Frequency Distribution of Type of Problems Related to Adverse Effects and 
Use (N=274) 
Problem Number Identified  N Percent (%) 
Additive effect 0 211 77.0 
1 47 17.2 
2 8 2.9 
3 6 2.2 
4 2 0.7 
Underuse 0 217 79.2 
1 42 15.3 
2 10 3.7 
3 2 0.7 
4 1 0.4 
7 1 0.4 
8 1 0.4 
Allergy 0 268 97.8 
1 5 1.8 
2 1 0.3 
Overuse 0 270 98.5 
1 3 1.2 
2 1 0.4 
Toxicity 0 272 99.3 
1 2 0.7 
 
The next problem was related to immunizations needed. Although 54 percent of patients 
had no problems related to immunizations, 19.8 percent of patients had at least two problems 
related to immunizations needed (see Table 3.17). Regarding social history and lifestyle issues, 
the most common problems were poor diet (14.2%), obesity (13.9%) and lack of exercise 
(11.0%) (see Table 3.18). 
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Table 3.17 Frequency Distribution of Type of Problems Related to Immunizations 
(N=274) 
Lack of Immunization Number Percent (%) 
0 148 54.0 
1 72 26.3 
2 29 10.6 
3 15 5.5 
4 7 2.6 
5 2 0.7 




Total does not equal 100 percent due to rounding 
 
Table 3.18 Frequency Distribution of Type of Problems
a
 Related to Social History and 
Lifestyle Issues (N=274) 
Problem Number Percent (%) 
Social History 
b 
Smoking 14 5.1 
Alcohol 1 0.4 
Lifestyle Issues  
Poor diet  39 14.2 
Obesity  38 13.9 
Lack of exercise  30 11.0 
Poor sleep 7 2.6 
a 
Problems were identified by students
   
b 
Problems related to caffeine consumption were included in drug-food interaction (see Table 3.15)  
 
Overall, patients understood drug indications and continuity of care with less than 7 
percent having problems in this area. (see Table 3.19). The last group of problems was related to 
disease monitoring and control. Diabetic patients had more problems related to their disease state 
than hypertensive and dyslipidemic patients. Most of the problems were related to poor self-
monitoring (see Table 3.20).  
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Table 3.19 Frequency Distribution of Type of Problems Related to Lack of 
Understanding Drug Indication and Continuity of Care (N=274) 
Problem Number Identified  N Percent (%) 
Lack of understanding 
drug indication 
0 257 93.8 
1 15 5.5 
2 2 0.7 
Continuity of care  0 261 95.3 
1 13 4.7 
 
Table 3.20 Frequency Distribution of Type of Problems Related to Disease Monitoring 
and Control (N=274) 
Type of Disease Problem  Number Percent (%) 
Hypertension  
(N= 221)  
Poor self-monitoring of 
blood pressure  
28 12.7 





Poor self-monitoring of 
blood glucose  
23 15.0 
Lack A1C check 5 3.3 
Lack of eye exam 6 3.9 
Lack of foot inspection  6 3.9 
Dyslipidemia 
(N= 186) 
Poor self-monitoring of 
lipid 
4 2.2 
Lack lipid panel  7 3.8 
 
Finally, Table 3.21 summarizes the means of all MHRPs identified by pharmacist-interns. 
The table shows that problems related to precaution/interactions/ contraindications (1.2 (±1.6)) 
and product selection (1.1(±1.2)) had the highest means among all types of problems; whereas 
lack of understanding drug indication and continuity of care had the lowest mean number of 
problems identified (see Table 3.21). 
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Table 3.21 Mean of Medication and Health-Related Problems Summary (N=274) 
Type of Problem Mean  Standard Deviation  
Precautions/interactions/contraindications 1.2 1.6 
Product selection  1.1 1.2 
Immunization 0.8 1.1 
Adverse effects and use 0.7 1.1 
Social histories and lifestyle issues 0.5 0.8 
Drug regimen  0.4 0.8 
Disease monitoring and control 0.3 0.8 
Lack of understanding drug indication and 
continuity of care 
0.1 0.4 
 
3.3.2 MTM Interventions 
MTM intervention refers to the interventions that pharmacist-interns provided 
prior to recommending any changes in a patient’s medications, health, social histories 
and/or lifestyle. It included contacting patients’ healthcare providers, asking patients to 
contact their healthcare providers, counseling patients/caregivers, education, and referral. 
Pharmacist-interns contacted 26.6 percent of patients’ healthcare providers; in contrast, 
29.2 percent of patients were asked to contact their own healthcare providers. 
Furthermore, 59.1 percent of patients/caregivers were counseled regarding their 
medications. Also, pharmacists-interns referred 42.0 percent of patients to other 
healthcare providers (see Table 3.22). 
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Table 3.22 Frequency Distribution of Type of Pharmacist-Intern Interventions  
(N=274) 
Type of Intervention Number  Percent (%) 
Education 193 70.4 
Counseled patient/caregiver 162 59.1 
Referral   115 42.0 







3.4 PHARMACIST-INTERN’S RECOMMENDATIONS AND OUTCOMES 
Based on patients’ MHRPs, pharmacist-interns provided patients with recommendations 
to address their problems. These recommendations were classified into to the following: (1) 
medications; (2) preventive care; (3) immunizations; (4) diabetes, hypertension, and 
dyslipidemia monitoring and control; and (5) smoking and alcohol. These were then further 
classified into: (a) outcomes related to medication-related recommendation (MRRs) (1 above) 
and (b) outcomes related to health-related recommendation (HRRs) (2-5 above). Pharmacist-
interns’ recommendations and outcomes results are detailed in the following paragraphs. 
3.4.1 Recommendations 
Between 20 percent and 30 percent received at least one recommendation related to 
changing prescription medication, changing schedule/duration, drug efficacy/safety lab 
monitoring, or OTC and herbal supplement. While less than 2 percent patients had 
recommendations related to request refill, change route and other, 7 to 15 percent of patients had 
at least one recommendation related to changing dose, adding drug(s), and discontinuing drug(s) 
(see Table 3.23). 
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Table 3.23 Frequency Distribution of Type of Pharmacist-Interns’ Recommendations Related 





Number Percent (%) 
Over-the-counter (OTC) 
medication and herbal 
supplement 
recommendation 
0 203 74.1 
1 52 19.0 
2 14 5.1 
3 3 1.1 
4 2 0.7 
Drug efficacy/safety lab 
monitoring 
0 192 70.1 
1 62 22.6 
2 11 4.0 
3 4 1.5 
4 3 1.1 
5 1 0.4 
6 1 0.4 
Change schedule/duration 0 193 70.4 
1 52 19.0 
2 18 6.6 
3 10 3.7 
4 1 0.4 
Change drug 0 206 75.2 
1 56 20.4 
2 8 2.9 
3 3 1.1 
4 1 0.4 
Change dose 0 235 85.8 
1 35 12.8 
2 3 1.1 
3 1 0.4 
Add drug 0 293 87.2 
1 30 11.0 
2 3 1.1 
4 2 0.7 
Discontinue drug 0 253 92.3 
1 19 6.9 
2 2 0.7 
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Table 3.23 (continued)Frequency Distribution of Type of Pharmacist-Interns’ 





Number Percent (%) 
Change dosage form 0 271 98.9 
1 2 0.7 
2 1 0.4 
Change drug to over-the-
counter (OTC) 
0 272 99.3 
1 2 0.7 
Change route 0 273 99.6 
1 1 0.4 
Request refill 0 273 99.6 
1 1 0.4 
 
Next, among recommendations related to preventive care, the highest percentage of 
recommendations was related to health lab monitoring, with 10.9 percent of patients having at 
least one recommendation (see Table 3.24). Moreover, recommendations related to health lab 
monitoring were identified as any recommendation related to monitoring patients’ bodily fluids 
(e.g., patient electrolyte and enzymes) except monitoring blood glucose and cholesterol.  
More than 10 percent of patients need immunizations with influenza (28.7%) followed by 
pneumococcal (19.7%), zoster (17.3), and tetanus (11.3%). Less than 4 percent were 
recommended to receive Hepatitis A or B, and Meningococcal vaccines (see Table 3.25).  For 
recommendations related to diabetes, hypertension, and dyslipidemia monitoring and control, the 
highest percentage of recommendations was related to hypertension care, with 23.4 percent of 
patients being recommended to monitor their blood pressure and/or bring a record of their blood 
pressure measurements, while 13.1 percent were recommended to monitor their blood glucose 
(see Table 3.26). Finally, 7.3 percent of patients received recommendations related to smoking, 
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and 3.3 percent of patients received recommendations related to alcohol consumption (see Table 
3.27).  
 
Table 3.24 Frequency Distribution of Type of Pharmacist-Interns’ Recommendations Related 
to Preventative Care (N=274) 
Type of Recommendations  Number of 
Recommendations  
Number Percent (%) 
Health lab monitoring 0 244 89.1 
1 25 9.1 
2 4 1.5 
4 1 0.4 
Cholesterol 0 259 94.5 
1 15 5.5 
Depression screening 0 273 99.6 
1 1 0.4 
Mammography/breast exam 0 274 100.0 
Pap smear 0 274 100.0 
Sigmoidoscopy/colonoscopy 0 274 100.0 





Table 3.25 Frequency Distribution of Type of Pharmacist-Interns’ Immunization 
Recommendations (N=274) 
Type of Recommendations  Number Percent (%) 
Influenza 78 28.7 
Pneumococcal 54 19.7 
Zostavax/shingles 48 17.3 
Tetanus 31 11.3 
Hepatitis B 10 3.7 
Hepatitis A 8 2.9 
Meningococcal 6 2.2 
 
 
Table 3.26 Frequency Distribution of Type of Pharmacist-Interns’ Diabetes, Hypertension, and 
Dyslipidemia Care Recommendations (N=274) 
Type of Recommendations  Number Percent (%) 
Blood pressure 
monitoring/request blood 
pressure lab  
64 23.4 
Blood glucose monitoring/ 
request A1c lab 
36 13.1 
Foot exam 21 7.7 
Eye exam 16 5.8 






Table 3.27 Frequency Distribution of Type of Pharmacist-Interns’ Education 
Recommendations (N=274) 
Type of Recommendations  Number Percent (%) 
Smoking cessation 20 7.3 
Alcohol  9 3.3 
 
 
3.4.2 MTM Outcome 
 
The following section describes the outcome of pharmacist-interns’ recommendations, 
which refers to the percentage of pharmacist-interns’ recommendations that were accepted by 
medical prescribers or patients. The outcomes were divided into outcomes related to medication-
related recommendations (MRRs) and outcomes related to health-related recommendations 
(HRRs). Table 3.28 shows that 28.9 percent of recommendations related to OTC medications 
and herbal supplements were accepted. Among prescription medications, recommendations 
related to drug discontinued had the highest percentage of acceptance (34.8%). 13.9 percent of 
the HRRs, which represent recommendations related to: (1) immunizations; (2) diabetes, 
hypertension, and dyslipidemia care; and (3) smoking and alcohol education, were accepted (see 













Table 3.28 Number, Number Accepted, and Percent Accepted of Pharmacist-Interns’ 
Medication and Health-Related Recommendation Outcomes 








Over-the-counter (OTC) and herbal supplements recommendations 
Over-the-counter (OTC) and 
herbal supplements 
97 28 28.9 
Prescription medication recommendations 
Drug discontinued 23 8 34.8 
Dosage form changed 4 1 25.0 
Schedule/duration changed 122 28 23.0 
Drug changed 85 17 20.0 
Drug added 44 8 18.2 
Drug efficacy/safety lab 
monitoring accepted 
119 12 10.1 
Dose changed 44 3 6.8 
Drug changed to over-the-
counter (OTC) 
2 0 0.0 
Route changed 1 0 0.0 




462 64 13.9 
    
Overall    
Overall health-related 
recommendations 
462 64 13.9 
Overall prescription medication 
recommendations 
542 105 19.4 
Overall medication and health-
related recommendations  
1004 169 16.8 
 
Tables 3.13 – 3.20 showed that students identified 935 medication-related problems 
(MRPs) (3.4 MRPs per patient) and 435 health-related problems (HRPs) (1.6 HRPs per patient), 
for a total of 1,370 medication and health-related problems (MHRPs) or 5 MHRPs per patient. 
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Students contacted 73 healthcare providers, counseled 162 patients/caregivers, and educated 193 
patients. Moreover, students provided patients with 542 MRRs (2 MRRs per patient) and 462 
HRRs (1.7 HRRs per patient), which means that overall, students provided patients with 1004 
medication and health-related recommendations (MHRRs) (3.7 MHRRs per patient). The 
percentage of students’ MRRs that were accepted was 19.4 percent and the percentage of 
students’ HRRs that were accepted was 13.9 percent, with an overall percentage of students’ 
MHRRs accepted was 16.8 percent. 
3.5 DATA MANAGEMENT 
3.5.1 Data Accuracy and Outliers 
For all study variables, univariate descriptive statistics such as means, frequencies, and 
standard deviations were conducted. During data cleaning, keystroke errors were identified and 
corrected. 
3.5.2 Multicollinearity 
Multicollinearity is a statistical problem that occurs when independent variables are 
moderately to highly correlated. It might create problems in a multiple regression analysis 
for the following reasons: 1) decrease the R2 (i.e., decrease the variance explained by the 
model); 2) confound the independent variables; and 3) increase the regression coefficient 
variances.75 As a result, the variance inflation factor (VIF), which is used to evaluate the 
linear regression between the independent variables, is used to detect multicollinearity.  
Consequently, the VIF was used to examine the regression model independent variables for 
multicollinearity. Importantly, it has been suggested that any independent variable VIF 
value greater than 10 might be considered for deletion.75 In this study, no independent 
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variables exceeded a VIF value greater than 3.1; as a result, all independent variables were 
maintained in the regression model. 
3.5.3 Evaluation of Assumptions 
Normality, linearity, homoscedasticity, and independency of residuals, which are the 
assumptions of regression, were evaluated before conducting the analysis. Univariate descriptive 
statistics and residual plots were used to test these assumptions. Assumption of normality was 
checked by examining skewness and kurtosis. Variables with skewness or kurtosis values greater 
than 3 or less than –3 may be considered as not normally distributed. The dependent variable, 
MHRPs resolved did not have any values out of range. In addition, the overall model residual 
plot was examined and visual inspection revealed a relatively normal distribution, linearity and 
no evidence of homoscedasticity or dependency among residuals. 
3.6 OBJECTIVE ANALYSIS  
The present study has four objectives and seven hypotheses. The first three objectives were 
descriptive, while multiple regression analysis was used to address the fourth objective. 
 
 Objective 1  
The first objective was to describe patients’ demographic characteristics (age, gender, 
race), social history (smoking, alcohol and caffeine consumption), and clinical characteristics 
(medical conditions, prescription medications, over-the-counter (OTC) medications and herbal 
supplements, and number of medical prescribers). Section 3.2 of this chapter provided the 
descriptive statistics to address this objective. 
 Objective 2 
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The second objective was to describe the number and type of medication and health-
related problems (MHRPs), MTM interventions, and MTM recommendations. Descriptive 
statistics were also used to address this objective (see Section 3.3). 
 Objective 3 
The third objective was to describe medical provider/patient MTM recommendation 
acceptance rates. Descriptive statistics (see Section 3.4) were used to address this objective. 
 Objective 4  
 The fourth and final objective was to determine what factors (baseline MHRPs, medical 
conditions, prescription medications, OTC medications and herbal supplements, MTM 
interventions, number of medical prescribers, and MTM recommendations) are related to the 
number of MHRPs resolved (change in MHRPs from baseline to follow-up). Regression analysis 











Table 3.29 Multiple Regression Analysis of Factors Related to MHRPs Resolved 






T-Value P-Value Variance 
Inflation 
Intercept 1 -0.015 0.26 0.000 -0.06 0.95 0.00 
MHRP baseline 1 0.077 0.04 0.127 2.09 0.04* 2.87 
Medical conditions 1 -0.044 0.04 -0.053 -1.14 0.25 1.67 
Prescription 
medications 
1 0.001 0.03 0.002 0.03 0.97 1.92 
OTC medications and 
herbal supplements 
1 -0.011 0.03 -0.014 -0.36 0.72 1.10 
MTM interventions 1 0.138 0.09 0.060 1.59 0.11 1.10 
Number of medical 
prescribers 
1 0.032 0.06 0.020 0.49 0.62 1.32 
MTM 
Recommendations 
1 0.513 0.05 0.715 11.37 <.0001* 3.08 
F statistic = 76.88; df = 7,240; Model p-value = < 0.001*; Adjusted R
2
 = 0.68 
*Statistically significant at p < 0.05. 
 
The overall regression model was statistically significant, F=76.88, df=7, 240, p<0.001. 
The adjusted R
2 
was 0.68, which indicated that 68 percent of the variance in the MHRPs resolved 
was explained by the model variables. Regarding significant factors, the number of MHRPs at 
baseline (β=0.127, t=2.09, p=0.04) and MTM recommendations (β =0.715, t=11.37, p<0.0001) 
were significantly related to the MHRPs resolved. Consequently, for every 1 point increase in 
MHRPs at baseline, the number of MHRPs resolved increased by 0.127. Similarly, for every 1 
point increase in MTM recommendations, the number of MHRPs resolved increased by 0.715. 
None of the other variables were significantly related. Below are the study’s hypotheses 
associated with this objective. 
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 Hypothesis 1: The number of baseline MHRPs will be positively and significantly 
related to the number of MHRPs resolved, while controlling for other factors. 
This hypothesis was accepted (β=0.127, p=0.04). The number of MHRPs at baseline was 
positively and significantly related to the number of the MHRPs resolved, while controlling for 
other factors. 
 
 Hypothesis 2: The number of medical conditions will be positively and significantly 
related to the number of MHRPs resolved, while controlling for other factors. 
This hypothesis was rejected (β=–0.053, p=0.25). The number of medical conditions was 
negatively related to the number of MHRPs resolved and this relationship was not statistically 
significant, while controlling for other factors.  
 
  Hypothesis 3: The number of prescription medications will be positively and 
significantly related to the number of MHRPs resolved, while controlling for other 
factors. 
This hypothesis was rejected (β=0.002, p=0.97). The number of medications was 
positively related to the number of MHRPs resolved, but this relationship was not statistically 
significant, while controlling for other factors. 
 
  Hypothesis 4: The number of OTC medications and herbal supplements will be 
positively and significantly related to the number of MHRPs resolved, while controlling 
for other factors. 
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This hypothesis was rejected (β=–0.014, p=0.72). The number of OTC medications 
and herbal supplements was negatively related to the number of MHRPs resolved and this 
relationship was not statistically significant, while controlling for other factors. 
  
  Hypothesis 5: The number of MTM interventions will be positively and significantly 
related to the number of MHRPs resolved, while controlling for other factors. 
This hypothesis was rejected (β=0.060, p=0.11). The number of MTM interventions was 
positively related to the number of MHRPs resolved, but this relationship was not statistically 
significant, while controlling for other factors. 
 
  Hypothesis 6: The number of medical prescribers will be positively and significantly 
related to the number of MHRPs resolved, while controlling for other factors. 
This hypothesis was rejected (β=0.020, p=0.62). The number of medical prescribers 
was positively related to the number of MHRPs resolved, but this relationship was not 
statistically significant, while controlling for other factors. 
 
 Hypothesis 7: The number of MTM recommendations will be positively and 
significantly related to the number of MHRPs resolved, while controlling for other 
factors. 
This hypothesis was accepted (β=0.715, p<0.0001). The number of MTM 
recommendations was positively and significantly related to the number of the MHRPs 
resolved, while controlling for other factors. 
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CHAPTER FOUR: DISCUSSION AND CONCLUSIONS 
4.1 BACKGROUND 
The literature has demonstrated that pharmacist-provided MTM services improve clinical 
and economic outcomes for patients and the healthcare system.
5-18
 However, pharmacists face 
barriers in providing MTM services.
24
 Training programs are available to address barriers for 
pharmacists,
27
 but training pharmacy students may be a more effective strategy for improving 
service provision in the future.
28,29
 Several C/SOPs have realized the importance of preparing 
their students to provide MTM.
32,35-42
 
4.2 PRESENT STUDY 
 This study examined the impact of third-year pharmacy students’ provision of MTM to 
community pharmacy patients on identifying and resolving patients’ medication and health 
related problems (MHRPs). A review of the literature revealed that studies of student-provided 
MTM have primarily focused on course description and students’ perceptions of the course. 
Those that have examined MTM course outcomes have focused on increasing students’ MTM 
knowledge and their abilities to provide MTM services,
32,35-39,41
 as well as improving patients’ 
understanding of their medications and their overall health.
34,36,37
 None of the studies, however, 
described the clinical impact of a required ‘entire’ MTM course in which all students received 
didactic lectures, completed a training program and provided MTM services to ‘real’ patients in 
community pharmacies. The impact of requiring all students in a C/SOP to provide MTM 
services might differ from having a selected number of students participate. The next section 
discusses the study results and compares its findings with those of previous similar studies. 
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4.3 STUDY FINDINGS 
This section highlights and compares the most salient results of the present study for each 
objective with those of similar studies that have previously been published. It also discusses the 
limitations of the present study as well as areas for future research.  
4.3.1 Patients’ Demographics, Social Histories, and Clinical Characteristics 
Objective 1 focused on describing patient demographics, social histories, and clinical 
characteristics. Patients’ average age was 63.8 (±14.5), which was similar the average age of 
patients in another MTM intervention study,
34
 although it was less than the average age of 
patients in other studies, which ranged from 75 to 81.
32,33
 Because the present study subjects 
were drawn from community pharmacies, they may not have been representative of Medicare 
patients, who are typically older. In the present study, a higher percentage of patients were 
female, which was similar to other studies.
5,32
 This is not surprising since women tend to be more 
proactive regarding their health than men.
77
 In the present study, the majority of patients were 
Caucasian (53.2%), followed by Hispanics (37.8%). Whereas, the U.S. Census Bureau reported 
that in 2011, Whites comprised approximately 80 percent of the U.S. and Texas population 
(78.1% vs. 80.9%, respectively) and Hispanics comprised 16.7% of the U.S. population and 
38.1% of Texas residents.
78
 Thus, the population of Hispanics were congruent with the state of 
Texas and Caucasians were underrepresented in the present study. Patients’ social histories (i.e., 
caffeine, alcohol, tobacco use) are rarely addressed in student-provided MTM studies. Compared 
to the 2008 U.S. census, the present study population had a lower proportion of alcohol drinkers 
(54.8% vs. 30.7%, respectively) and smokers (23.8% vs. 12.4%, respectively).
60
 
Regarding patients’ clinical characteristics, the mean number of patients’ medical 
conditions was 6, which is similar to other studies (range of 5.5-6.4).
14,32
 When compared to the 
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Department of Health and Human Services 2010 report of patients over 65 years, 
79
 the present 
study’s subjects had a higher prevalence of hypertension (68.4% (65-74 years); 80.4% (≥75 
years) vs. 80.7%, respectively), dyslipidemia (51.8% vs. 67.9%, respectively), and diabetes 
(26.9% vs. 55.8%, respectively). Accordingly, more than half of the patients in the present study 
used blood pressure agents, cholesterol lowering agents, analgesic agents, and diabetic agents. 
Perhaps the higher prevalence could be due to the significant number of Hispanics in the study 
population, who are known to have disparities with these disease states.
80-82
 Having all three 
disease states together (i.e., metabolic syndrome) is a very serious condition that can lead to 
additional morbidity and mortality. Pharmacist-interns or pharmacists can be very instrumental 
in counseling patients not only on one specific disease state, but how the combination of the 
three can result in poor outcomes if not managed appropriately. 
The mean number of OTC medications used by patients was 2.2, which was similar to 
other studies (range 1.8 - 3.9).
32,34
 At least one herbal supplement was used by 19 percent of 
patients which was similar to national estimates of 17.7 percent.
83
 However, the present study 
may have over or underestimated herbal supplement use because pharmacist-interns sometimes 
miscoded herbal supplements as OTC medications (e.g., multivitamins) and vice versa. Thus, 
additional education regarding complementary and alternative medications (CAM), namely 
herbal supplements, is warranted for student pharmacists. The majority (63% to 72%) of CAM 
users did not disclose at least one type of CAM.
84
 Therefore, educational components should 
include familiarity with various types of CAM used in their area, knowledge regarding potential 
medication-related problems, as well as strategies to encourage patients to disclose CAM use. 
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4.3.2 Medication and Health Related Problems (MHRPs) and Student-Pharmacists MTM 
Interventions and Recommendations  
In the present study, MHRPs were calculated as a percent of patients (N=274), whereas, 
several studies in the literature calculate the frequency of problems among all MHRPs. Thus, 
when appropriate, comparisons will be made among all MRPs (N=935), all HRPs (N=435), and 
total MHRPs (N=1,370). MHRPs identified by student-pharmacists at baseline can be divided 
into groups depending on the type of problem. These groups were initially divided into 
medication-related problems (MRPs) and health-related problems (HRPs). MRPs are divided 
into problems related to: (1) drug product selection; (2) drug regimen; (3) 
precautions/interactions/contraindications; and (4) adverse effects and use. Health-related 
problems are divided into: (1) immunizations; (2) social histories and lifestyle issues; (3) lack of 
understanding drug indication and continuity of care; and (4) disease monitoring and control. 
The following section will highlight the most frequent problems within each group of problems 
and compare them with those identified in other student-provided and pharmacist-provided 
MTM studies.  
When examining each group of MRPs (see Tables 3.13 - 3.16), problems related to 
precautions/interactions/contraindications and product selection had the highest overall means 
1.2 (±1.6) and 1.1(±1.2), respectively. However, the lowest means for MRPs were related to drug 
regimens or adverse effects and use, which might indicate that pharmacist-interns had difficulty 
identifying these types of problems.  
The most prevalent problems within the drug product selection group were OTC and 
herbal medication use, cost/formulary exchange, and duplication. Pharmacist-interns identified at 
least one problem related to OTC medications in 20.4 percent of patients, while Cerulli et al. 
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found 44 percent of patients had problems related to nonprescription medications.
34
 The present 
study’s results may have been lower because OTC and prescription drug interactions were coded 
as drug-drug interactions versus an OTC medication problem. OTC medications and herbal 
supplements may interact with prescription medications and cause serious adverse drug 
reactions.
85
 With 81 percent of the patients using at least one product in the present study, 
pharmacists and pharmacist-interns have an opportunity to identify, prevent, and resolve these 
types of problems. Thus, they should routinely ask patients about OTC and herbal supplements 
that they are using and ensure appropriate use or identify an alternative. The second most 
prevalent problem was cost/formulary interchange (14.2%). Other pharmacist-provided MTM 
studies identified cost issues at higher prevalence rates (33.3% - 85%,)
7,10,12
 Perhaps initial MTM 
interventions were successful in identifying cost savings and current MTM programs are 
focusing on other MRPs. However, when examining studies of student-pharmacist provided 
MTM, only 6.0 percent of MRPs were related to cost,
42
 which is lower than the present study’s 
findings. The difference between pharmacist and student provided MTM may be that 
pharmacists are more familiar with the various formulary tiered copayment structures and they 
can readily identify cost savings options. Increased medication costs are associated with poor 
medication adherence, which can lead to suboptimal health outcomes.
86
 To help improve 
medication adherence and outcomes, pharmacists and pharmacist-interns can help patients 
identify less costly alternatives by using strategies such as switching to generics, using formulary 
medications, educating about patient assistance programs, or identifying discount coupons. In the 
present study, 4.4 percent of all MRPs (n=935) were related to drug duplication, which is within 




The most frequent problems among patients related to drug regimen were dose (14.6%) 
and schedule duration (14.2%). Furthermore, among all MRPs identified, the percentage of 
problems related to dose and schedule duration were, 4.8 percent and 5.8 percent, respectively. 
Other studies showed that problems related to dose ranged from 11.2 percent –24.8 
percent,
14,32,34,37
 and problems related to schedule duration was 14.4 percent.
37
 The present 
study’s frequency was lower than other studies, which were conducted with pharmacist- 
provided and student-provided MTM services. Perhaps this is an area where student pharmacists 
can receive additional education, or it could be reflective of the study subjects’ actual problems 
in this area.  
Regarding the type of problems related to precautions/interactions/ contraindications, 
48.5 percent of patients had a drug interaction identified. Among all MRPs identified by 
pharmacist-interns, 26.7 percent were related to drug-drug interactions, which was higher than 
Hata et al. (14.9%).
37
 This finding may have been the result of coding the interaction between 
OTC medications and prescription medications as drug-drug interactions instead of 
precautions/interactions/contraindications.  
Furthermore, pharmacist-interns identified at least one problem related to drug adverse 
effects in 23.0 percent of patients, which accounted for 9.5 percent of all MRPs identified. Other 
studies also documented the problems related to drug adverse effect and found them to range 
from 9.0 percent - 18.2 percent of MRPs.
14,32,34,37
 Due to the presence of other MRPs categories 
(e.g., allergy and toxicity) in the present study, which might interfere with problems related to 
adverse drug reactions, the current study finding is greater than other studies.  
Regarding the total number of MRPs, the present study documented 935 MRPs, or an 
average of 3.4 MRPs per patient. This result was higher than what other student MTM studies 
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found (0.9 – 2.0 MRPs per patients).
34,36,37
 The reason for the discrepancy could be that other 
studies offer the MTM course as a part of a course (versus the entire course), and that students 
were not required to complete the MTM training certificate program, “Delivering Medication 
Therapy Management Services in the Community.”34,36,37  
In contrast to other studies, pharmacist-interns in this study identified problems with 
immunizations. This could be the result of the requirement to complete an immunization 
certificate program before registering for the course. Importantly, pharmacist-interns found that 
54 percent of patients were up-to-date on immunizations. This finding should be viewed with 
caution because it is possible that patients’ recall may have been unreliable. C/SOPs should offer 
training programs for students to become immunizers. Pharmacists and pharmacist-interns can 
play a significant role in ensuring that patients receive needed vaccinations. They can also 
educate patients on the individual and public health benefits of vaccines. Regarding lifestyle 
issues, over 10 percent of the patients were identified as having poor diet (14.2%), obesity 
(13.9%) and lack of exercise (11.0%), which may be linked to the high prevalence of 
hypertension, diabetes, and dyslipidemia in the study population. This highlights the importance 
of not only educating patients about their medications, but also making sure they understand how 
lifestyle issues can impact their outcomes. 
Once pharmacist-interns identified MHRPs, the next step was to intervene with the 
patient or their providers by pharmacist-interns contacting physicians, patients contacting 
physicians, educating patients, counseling patients/caregivers, and referring patients. Pharmacist-
interns contacted about one-fourth (26.6%) of patients’ physicians. This result is lower than one 
study related to MTM in which only 51.5 percent of physicians reported that they never really 
had contact with pharmacists regarding patients’ medications.
20
 More frequently, pharmacist-
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interns asked patients to contact their physicians (29.2%). Getting patients more involved and 
encouraging them to have more ownership of their healthcare is also important in MTM 
provision.
63
 Time constraints within the pharmacy may also have been a reason for this finding. 
The present study defined patient/caregiver counseling (59%) as any intervention that included 
providing patients or their caregivers with verbal or written instructions on taking their 
medications, while education (70.4%) was defined as any intervention that included providing 
the patients with verbal or written instructions on overall health. Because this study classified 
these interventions differently than other studies, comparisons could not be made. Referrals were 
made to approximately 40 percent of patients’ providers; however, documentation regarding to 
whom (e.g., primary care, specialist, dieticians, and behavioral counseling) was not well 
documented.  Pharmacists and pharmacist-interns should be more detailed when documenting 
interventions so that timely and appropriate follow up can occur.  
Next are the pharmacist-interns’ recommendations related to MHRPs. Recommendations 
related to drug efficacy/safety lab monitoring (29.9%) and recommendations related to changing 
medications schedule/duration (29.6%) occurred more frequently than other recommendations 
related to medications. The number of recommendations related to drug efficacy/safety lab 
monitoring was high because combining these individual problems (i.e., problems related to: (1) 
drug safety and (2) drug efficacy) resulted in a frequency of 25.2 percent. The number of 
recommendations related to changing medications schedule/duration was high because these 
occurred when patients had problems related to drug schedule/duration, drug-drug interaction, or 
drug-food interaction (combined frequency = 67.8%). Drug and food interactions problems were 
included in these recommendations because they involved changing the drug schedule. For 
example, if two drugs were taken together and interacted, the recommendation may have been to 
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take one in the morning and the other at bedtime. Of the medication-related recommendations 
(MRRs), 15.7 percent were related to changing medications, whereas Donihi et al. found that 
18.5 percent of students’ MRRs were related to changing medications.
41
 The lowest number of 
recommendations was related to changing the route of drug administration.
41
 Because MTM was 
provided in community pharmacies, recommendations related to changing the route of 
medication (e.g., from oral to intravenous) were likely to be infrequent. The number of 
recommendations related to immunizations indicated that pharmacist-interns did not recommend 
that all patients who needed them receive their vaccines. For example, 111 patients mentioned 
that they did not receive their influenza vaccine, but only 78 of those patients were recommended 
to receive it. Similarly, the number of recommendations regarding smoking and alcohol 
consumption indicated that pharmacist-interns did not recommend that all patients who were 
smokers (n=33) quit smoking or that all patients who drank alcohol (n=82) stop, if 
contraindicated, or decrease alcohol consumption, if warranted.  
4.3.3 MTM Outcome 
This study’s MTM outcomes represent the pharmacist-interns’ MTM recommendations 
that were accepted by either medical prescribers or patients. Of the pharmacist-interns’ 
recommendations related to OTC medications, 28 percent were accepted. ‘Drug discontinuation,’ 
followed by ‘change of dosage form’ were the recommendations with the highest rates of 
acceptance, whereas recommendations related to change of drug were the least accepted. 
Overall, 19.4 percent of the medication-related recommendations (MRRs) were accepted by 
either medical prescribers or patients. This percentage of acceptance is lower than what was 
found in the literature (52.6% – 86%). 
34,41,42
 Three issues that may have contributed to the low 
acceptance rate of recommendations in the present study were the inclusion of community 
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pharmacy patients, who may not have had established primary care homes; thus making follow-
up with providers difficult. A second reason was lack of time for follow up. Pharmacist-interns 
were working in the pharmacy setting for short periods of time, which may have precluded 
appropriate follow-up. A third reason is that the MHRPs may not have been a problem. For 
example, a patient may have been identified as having duplicate therapy. However, if the 
provider confirms that the therapy is needed, the recommendation to discontinue a therapy was 
not accepted. Finally, 13.9 percent of pharmacist-interns’ recommendations related to preventive 
care were accepted. This category included recommendations related to preventive care, 
immunization, diabetes, hypertension, dyslipidemia, and education.  This number, although it is 
lower than the findings of a pharmacist-provided MTM study (44.3%)
74
, shows that there is 
room for improvement in getting patients to be more proactive regarding their health. Patients 
may need conditional follow-up and reminders to make behavior change. Teaching students 
motivational interviewing may be a strategy to help patients make this change.    
4.3.4 Number of Medication and Health Related Problems (MHRPS) Resolved 
Examining the factors that are associated with the number of medication and health related 
problems (MHRPs) resolved was the fourth objective of this study. Factors that were assumed to 
predict the resolution of MHRPs were as follows: Number of MHRPs at baseline, medical 
conditions, medications, OTC medications and herbal supplements, MTM interventions, number 
of medical prescribers, and MTM recommendations. This study hypothesized that those 
predictor variables (independent variables) would positively correlate with the number of 
MHRPs resolved. One study showed that patients who have a high number of medications and/or 
a high number of medical conditions have a high number of MHRPs,
87
 which would 
theoretically lead to a high number of MHRPs resolved. Likewise, patients who have a high 
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number of prescribers tend to have more MHRPs.
88
 The present study’s overall multiple 
regression model was statistically significant (F = 76.88, df=7, 240, p <0.001). Among 
regression model predictors, the number of MHRPs at baseline and the number of MTM 
recommendations were significantly and positively correlated with the number of MHRPs 
resolved. It is not surprising that patients who present with multiple problems will have a higher 
frequency of problem resolution. However, the positive relationship between number of 
recommendations and MHRPs resolution may indicate that pharmacists and pharmacist-interns 
should not be hesitant to make recommendations and that they should follow up with healthcare 
providers once the recommendation has been made. 
4.4 STUDY LIMITATIONS 
The present study has several limitations. First, patients who received MTM services were 




, assisted living facility centers, or were patients 
who were interested in receiving the MTM services. These patients might not be considered 
eligible under Medicare’s Part D MTM program eligibility criteria.
4
 However, because the 
average age of study’s patients was 63.8, 93.9 percent had more than one medical condition, 
95.3 percent had more than three prescriptions medications, and the patients had many MHRPs, 
those 65 years and older might be eligible under the Part D program. Next, because of patient 
self-reports, the accuracy of information, such as the acceptance of MTM recommendations, is 
uncertain. Furthermore, in some cases, two pharmacist-interns were asked to provide MTM 
services to same patient. In this situation, pharmacist-interns would interview a patient at the 
initial visit to collect his or her information, and then they were asked to work individually on 
identifying the patient’s MHRPs, and then provide him or her with one set of recommendations. 
Because the pharmacist-interns were encountering the patient together, their MTM provision 
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should be identical, but this was not always the case. To control for this, the present study 
combined documentation for the patient cases. As with any “chart review” study, the data is only 
as accurate as the accuracy and completeness of the documentation. In addition, students 
documented their findings and recommendations in a written format. Thus interpretation of 
problems, interventions, and recommendations were at the discretion of the researcher and could 
have been biased or misrepresented.     
4.5 STUDY CONCLUSION 
Third-year pharmacy students, after completing an MTM certificate training program and 
listening to MTM lectures, provided MTM services for patients in community pharmacies. 
Students had an impact on patients’ medication and health related outcomes. Adult patients 
(N=274) with multiple medications and medical conditions received MTM services and 1,370 
MHRPs were identified and 1004 MHRRs were provided. The most prevalent problem was 
related to precautions/interactions/contraindications, and the most frequently provided 
recommendation was related to change in medication schedule and duration of medication use. 
Although the overall acceptance rate was 16.8 percent, students were unable to continue follow 
up with medical providers/patients due to limited timespan of the class. MHRPs baseline and 
MTM recommendation were positively and significantly related to the number of MHRPs 
resolved. 
Future research needs to estimate the economic, in addition to the clinical impact of 
intern pharmacists’ MTM service provision for individual patients the health care system overall. 
For example, estimating the direct and indirect cost avoidance as a result of pharmacy students 
providing MTM services is important. Estimating the impact of this type of MTM service on 
helping the elderly and low-income patients avoid clinical and economic burdens is particularly 
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important. Also, measuring how MTM provided by students or pharmacists can help Medicare 
patients who are in the “donut hole” will be beneficial. 
Regarding the MTM course, it is important to continue following up with medical 
providers and patients regarding students’ recommendations. Also, preparing the students to 
effectively document their provision of MTM will help to accurately detect their impact. 
Furthermore, providing students with a detailed list of MHRPs might help them in documenting 
their services, which in turn would help in estimating their impact. In addition, measuring the 
students’ intention to provide MTM services and their therapeutic skills before and after 
providing MTM services would be a useful way to estimate the impact of MTM courses on 
patients and students alike. The UT-COP Clinical Skills: Community Care was instrumental in 
identifying 3.4 MRPs and 1.6 HRPs per patient in a community pharmacy setting. Although the 
overall acceptance rate (16.8%) was low, it is likely that continual follow up and improved 






















































Clinical Skills:  Community Care Course Syllabus (Pilot Course) 
 
PHR 261J - Clinical Skills:  Community Care 
Unique #59476 
Fall 2010 
Course Coordinator:   Sharon Rush, R.Ph. 
   PHR 2.222G, 232-3463 
   sharon.rush@austin.utexas.edu 
   Office hours by appointment  
Course Administrative Coordinator:   Sherrie Bendele 
      PHR 5.110, 232-2630 
      s.bendele@austin.utexas.edu 
      
Course Objectives: 
 To provide P3 student-interns with an activity-based Intermediate Pharmacy 
Practice Experience in a community/ambulatory care pharmacy practice setting 
 To integrate basic clinical and scientific knowledge in the care of ambulatory 
patients in actual practice settings 
 To train student-interns to perform Medication Therapy Management 
 To better prepare student-interns for Advanced Pharmacy Practice Experiences in 
the P4 year 
 To develop a better understanding of the profession of pharmacy from a community 
pharmacy perspective 
 Student-interns will be able to demonstrate the following: 
o Basic understanding of: 
 Medication Therapy Management  
 Public Health 
 Patient Safety 
 Other experiences that may involve Drug Utilization Review, Drug 
Information, Immunizations or Health Screenings 
 
General Course Description: 
   Prior to the P3 year, student-interns will be distributed to four campuses:  UT Austin, 
UTHSCSA, UTEP and UTPA.  Within these geographic areas, student-interns will be 
assigned to a preceptor and a P4 student mentor and will participate in 
community/ambulatory care-specific activities.  Flexibility to accommodate the student-
intern’s class and lab schedule, preceptor availability and patient load will be observed.  
Student-interns will complete 80 hours over the course of the semester at approximately 4 
to 5 hours per week.  During this time, student-interns are required to participate in the 
following: 
 
 Activities associated with Medication Therapy Management (MTM) in Pharmacy 
Practice:  Core Elements of an MTM Service Version 2.0.  These activities include 
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medication therapy review, development of personal medication records and 
medication-related action plans, intervention and referral, documentation and 
follow-up.  Student-interns will accomplish this by participating in the following: 
o Completion of APhA’s Delivering Medication Therapy Management Services in 
the Community national certificate training program 
o Completion of five Comprehensive Medication Review MTM (CMR MTM) 
cases that must be turned in to the Course Coordinator  
 Public health promotion through the development of a health and wellness-related 
project as determined by the practice site and student. For this course, public health 
is defined as anything that affects the health and wellbeing of a patient, such as 
disease prevention, immunizations, health screenings, etc.   
 Patient safety exercise -For this course, patient safety is defined as any aspect of the 
prescription process that may affect the accurate delivery and administration of a 
medication.  This process follows the prescription from the prescribing physician to 
the actual use by the patient.  The patient safety exercise includes: 
o The completion of one of the following: 
 Health Literacy Assessment.  Refer to AHRQ Pharmacy Health Literacy 
Center at 
http://pharmacyhealthliteracy.ahrq.gov/sites/PharmHealthLiteracy/
default.aspx.  –OR-- 
 Medication Safety Self Assessment at 
http://www.ismp.org/selfassessments/Book.pdf. 
o County census search at http://2010.census.gov Data Tools at bottom of 
page Interactive Internet Tools  Censtats USA Counties Data Select 
state and county.  Pick “General Profile” and hit “Go”. 
o Completion of one Medication Calendar for an MTM patient. 
 Reflections on experiences will be required at designated times.  These reflections 
give the student-intern an opportunity to think about what they have learned and 
examine the procedures used in completing each exercise.  It is strongly encouraged 
to write the reflection immediately upon completion of the exercise while it is still 
fresh in the student-intern’s mind.   It is also strongly recommended that reflection 
notes are written on a weekly basis to keep track of highlights and thoughts that 
occur.  Reflections need to be one to two pages in length. 
 Additionally, student-interns are required to participate in a minimum of one of the 
following activities to build upon previous learning and skill development: 
o Promotion of immunizations through patient education and assessment or 
administration of vaccines if the student is a certified immunizer. 
o Demonstration of patient assessment skills through health screenings, etc. 
o Drug Utilization Review 
o Drug Information request 
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o “Delivering Medication Therapy Management Services in the Community” 
certification course booklet 
o “Medication Therapy Management in Pharmacy Practice:  Core Elements of an 
MTM Service Model” – Version 2.0,  March 2008, APhA website at 
www.pharmacist.com  
o “Motivational Interviewing”  -  APhA CE at www.pharmacist.com 
 Suggested: 
o “Medication Therapy Management Services:  Creating a Patient Care Process 
for MTM in Your Practice” – Module 4, APhA CE 2007 at www.pharmacist.com 
o “Why Pharmacists Belong in The Medical Home” – Marie Smith, David W. 
Bates, Thomas Bodenheimer, and Paul D. Cleary.  Health Affairs, May 2010, 
29:5 





Experience Form Where to locate 
form 
Where to submit 
form 
Medication Therapy Management  
 Medication Therapy Review (MTR) 
 Personal Medication Record (PMR) 
 Medication-Related Action Plan (MAP) 
 Intervention and/or Referral 
 APhA Statement of Completion 
 Reflection 
 Statement of 
Completion in 
MTM workbook 




 Reflection found 
on Blackboard 
 Statement of 
Completion to 
Sherrie Bendele 
 All other MTM 
forms are 
submitted on 
Blackboard.  Keep 
copies in your 
notebook.   
 Reflection form is 
submitted on 
Blackboard. 
Experience Form Where to locate 
form 





 Outline is 
student-intern’s 
own format.   
 Show outline to 
preceptor and 
keep in notebook 
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 Reflection found 
on Blackboard 




 Health Literacy 
 Patient Safety 
 Census Search 
 Medication Calendar 
 Reflection 
 Health Literacy, 










 Health Literacy, 
Patient Safety and 
Census Search are 
shown to 
preceptor and 






Drug Information and Drug Utilization 
Review 
 Documentation forms 
 Reflection 
 Blackboard  Documentation 
forms – show to 
preceptor and 




Health Screenings and Immunizations 
 Reflection 
 Blackboard  Blackboard 
 
Course Grade:   
This is a 2-hour experience-based course graded “Credit/Fail”.  To receive credit for this 
course, the student-intern must satisfactorily complete all course requirements.  Failure to 
successfully complete any of the following course requirements will result in automatic 
failure of the entire course: 
 Completion of 80 experiential hours 
 Completion of APhA’s Delivering Medication Therapy Management Services in the 
Community certification course and all required activities and documentation 
 Completion and documentation of five CMR MTM cases 
 Completion of Public Health project and all required activities and documentation 
 Completion of Patient Safety Assessment and all required activities and 
documentation 
 Completion of a minimum of one elective experience and all required activities and 
documentation 
 Reflections 
o  MTM case 
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o  Public Health project 
o Patient Safety exercise 
o Elective exercise 
 
Timeline: 
Deadlines for required documentation are on the timeline which is the last page of the 
syllabus.  All required documentation for the week must be submitted by 5pm that Friday. 
 
Schedules: 
Schedules will be determined by student-intern and site preceptor.  The number of hours 
scheduled each week may vary depending on the student-intern, the preceptor and the 
practice site’s activities.  All efforts will be made to accommodate the schedules of involved 
entities.  Weekend and evening hours may be necessary to fulfill all course requirements, 
i.e. Saturday screenings, immunization clinics, etc.  Schedules for the following month need 
to be determined by the 22nd day of the month.  A week’s notice is required for any changes 
to the schedule and must be approved by the student-intern and site preceptor.  It is 
required that student-interns be present on all days of the scheduled rotation period.  
Regular and prompt attendance mimics the actual working world.  Holidays may be 
observed by the student-intern provided the preceptor approves.  Religious holidays may 
be observed according to University policy.  The student-intern must make up the hours 
missed during this time. 
 
The student-intern’s time should be divided up as follows: 
 Medication Therapy Management - ~70% 
 Public Health - ~10% 
 Patient Safety - ~10% 
 Elective Experience - ~10% 
These are approximations and may vary slightly between sites. 
 
Hours Sheet: 
The Hours Sheet is designed to keep track of all hours worked each week plus any 
scheduled required documentation.  It is the student-intern’s responsibility to ensure this 
sheet is complete, accurate and current.  All entries need to be completed in ink.  At the end 
of the shift, the student-intern or preceptor must record the shift and hours completed and 
review any required documentation for that week.  If a preceptor feels that there is 
reason to believe that a student-intern may be misrepresenting his or her hours as 
recorded on the hour sheet, the Course Coordinator should be notified immediately.  
This type of behavior constitutes academic dishonesty and will not be tolerated.  The 
penalty for falsification of hours is failure of the course. 
 
Standards of Conduct: 
 Student-interns are required to abide by the facility’s Health Information Portability 
and Accountability Act (HIPAA) policies.  You may be required to sign a temporary 
HIPAA form at your site. 
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 Student-interns must abide by all laws and regulations pertaining to a student-
intern as defined by the Texas Pharmacy Act and Rules.  Violation of these laws and 
regulations may jeopardize the intern’s privilege to become a registered pharmacist 
in Texas and may also result in failure of the course and dismissal from the College 
and/or the University. 
 Student-interns will be removed from a practice site for conduct deemed 
unprofessional by the preceptor and/or Student Affairs Office, or if the student-
intern’s actions endanger a patient’s health or welfare.  Removal from a practice site 
may result in failure of the course. 
 Professional demeanor and dress are expected and required throughout the course.  
The student-intern is representing the University of Texas College of Pharmacy and 
is expected to behave accordingly. 
 
General Requirements: 
 Completion of the following UT Compliance Modules: 
o Bloodborne Pathogens at 
https://utdirect.utexas.edu/cts/class.WBX?s_course_comp=0&s_course_prefix=CW&s_course_number
=0533 
o General HIPAA Privacy at 
https://utdirect.utexas.edu/cts/class>WBX?s_course_comp=0&s_course_prefix=CW&s_course_numbe
r=0500 
o Log into both of the websites above, or alternatively 
https://utdirect.utexas.edu/cts/index.WBX and click on Compliance Training 
o Complete BOTH courses and take the quiz at the end of each course 
o You may be prompted or have the option to print a certification of 
completion.  Please print these for your records.   We verify your 
participation in another way. 
 Student-interns need to provide a binder to keep all records and documentation. 
 E-Mail – Student-interns are required to be accessible via e-mail and to check e-mail 
at a minimum of two times weekly per University policy.  Additionally, it is 
mandatory that students communicate any changes in e-mail or regular mail 
addresses to the Office of Student Affairs and the Course Coordinator immediately. 
 Transportation – The student-intern is responsible for his/her own transportation 
to and from any assigned practice site or class activity.  Prompt arrival is expected.  
 Dress Code - UT student-intern name badges, business casual dress and white 
jackets are to be worn at all times while fulfilling the course objectives.   Blue jeans 
and open-toed shoes are unacceptable dress even if the practice site allows it.  The 
Texas State Board of Pharmacy requires you to have your intern card in your 
possession at all times. 
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Clinical Skills:  Community Care Course Syllabus 
 
PHR 287H - Clinical Skills:  Community Care 
Unique #59965, 59975, 59980, 60000, 60005, 60010, 60015, 60020, 60025 
Fall 2011 
Course Coordinator:   Sharon Rush, R.Ph. 
   PHR 2.222G, 232-3463 
   sharon.rush@austin.utexas.edu 
   Office hours by appointment  
Course Administrative Coordinator:   Sherrie Bendele 
      PHR 5.110, 232-2630 
      s.bendele@austin.utexas.edu 
     Office hours by appointment 
 
Course Goals: 
 The Community Introductory Pharmacy Practice Experience (IPPE) is an activity-
based experience in a community/ambulatory care pharmacy practice setting 
designed to help pharmacist-interns develop a better understanding of the 
profession of pharmacy from a community pharmacy perspective.  This experience 
will better prepare pharmacist-interns for their Advanced Pharmacy Practice 
Experience. 
        
Course Objectives: 
 Pharmacist-interns will be able to integrate basic clinical and scientific knowledge in 
the care of ambulatory patients in actual practice settings through the performance 
of Medication Therapy Management 
 Pharmacist-interns will review patient medication histories and develop action 
plans to optimize a patient’s medication therapy and outcomes 
 Educate patients on health and wellness through the development and execution of 
a public health project 
 Assess patient safety by performing drug utilization reviews and drug information 
requests 
 Demonstrate longitudinal learning through continued application of patient 
assessment and immunizations 
 
Course Requirements: 
   Prerequisites:  Completion of the second professional year in the College of Pharmacy. 
Prior to the P3 year, pharmacist-interns will be distributed to four campuses:  UT Austin, 
UTHSCSA, UTEP and UTPA.  Within these geographic areas, pharmacist-interns will be 
assigned to a preceptor and will participate in community/ambulatory care-specific 
activities.  Flexibility to accommodate the pharmacist-intern’s class and lab schedule, 
preceptor availability and patient load will be observed.  Pharmacist-interns will complete 
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80 hours over the course of the semester at approximately 4 to 6 hours per week.  During 
this time, pharmacist-interns are required to participate in the following: 
 
 Activities associated with Medication Therapy Management (MTM) in Pharmacy 
Practice:  Core Elements of an MTM Service Version 2.0.  These activities include 
medication therapy review, development of personal medication records and 
medication-related action plans, intervention and referral, documentation and 
follow-up.  Pharmacist-interns will accomplish this by participating in the following: 
o Completion of APhA’s Delivering Medication Therapy Management Services in 
the Community national certificate training program 
o Completion of five Comprehensive Medication Review MTM (CMR MTM) 
cases that must be turned in to the Course Coordinator  
 Public health promotion through the development of a health and wellness-related 
project as determined by the practice site and pharmacist-intern. For this course, 
public health is defined as anything that affects the health and wellbeing of a patient, 
such as disease prevention, immunizations, health screenings, etc.   
 Patient safety exercise - For this course, patient safety is defined as any aspect of the 
prescription process that may affect the accurate delivery and administration of a 
medication.  This process follows the prescription from the prescribing physician to 
the actual use by the patient.  The patient safety exercise includes: 
o Completion of one Drug Utilization Review  
o Completion of one Drug Information Request 
o Completion of one Medication Calendar for an MTM patient. 
 Reflections on experiences will be required at designated times.  These reflections 
give the pharmacist-interns an opportunity to think about what they have learned 
and examine the procedures used in completing each exercise.  It is strongly 
encouraged to write the reflection immediately upon completion of the exercise 
while it is still fresh in the pharmacist-intern’s mind.   It is also strongly 
recommended that reflection notes are written on a weekly basis to keep track of 
highlights and thoughts that occur.  Reflections need to be one to two pages in 
length. 
 Pharmacist-interns will participate in a minimum of two of the following elective 
activities to build upon previous learning and skill development: 
o Administration of immunizations 
o Demonstration of patient assessment skills through health screenings, etc. 
o Other activities assigned by preceptor 
 
NOTE:  Prescription dispensing activities should comprise less than 5% of the pharmacist-




o  “Delivering Medication Therapy Management Services in the Community” 
certification course booklet 
o “Medication Therapy Management in Pharmacy Practice:  Core Elements of an 
MTM Service Model” – Version 2.0,  March 2008 at  
http://www.accp.com/docs/positions/misc/CoreElements.pdf 
o Various handouts on Motivational Interviewing: 
 Mirixa tip sheet – in IPPE binder packet 








o “Medication Therapy Management Services:  Creating a Patient Care Process 
for MTM in Your Practice” – Module 4, APhA CE 2007 at 
http://www.pharmacist.com/AM/Template.cfm?Section=Home2&TEMPLAT
E=/CM/ContentDisplay.cfm&CONTENTID=19018 
o “Why Pharmacists Belong in The Medical Home” – Marie Smith, David W. 









   This course utilizes Blackboard for communication, distribution of course materials and 
documents, and to submit assignments.  Blackboard is a web-based course management 
system with password-protected access at http://courses.utexas.edu.  You can find support 
for using Blackboard at the ITS Help Desk at 512-475-9400 Monday through Friday, 8am to 











Experience Form Where to locate 
form 
Where to submit 
form 
Medication Therapy Management  
 Medication Therapy Review (MTR) 
 Pharmacist Action Plan  
 Personal Medication Record 
 APhA Statement of Completion 
 MTM Mini-Reflection 
 Self-study test from MTM booklet 
 Pre-case workup from MTM booklet 
 Reflection 
 Statement of 
Completion, self-
study test and 
MTM Pre-case in 
MTM workbook 
 MTM Mini-
Reflection in IPPE 
binder packet 




 Reflection found 
on Blackboard 
 Statement of 
Completion, self-





 All other MTM 
forms are 
submitted on 
Blackboard.  Keep 
copies in your 
notebook.   






 Outline is 
student-intern’s 
own format.   
 Reflection found 
on Blackboard 
 Show outline to 
preceptor and 
keep in notebook 




 Drug Utilization Review (DUR) 
 Drug Information Request (DI) 
 Medication Calendar 
 Reflection 
 Patient Safety 
Documentation 
form for DUR and 






 Patient Safety 
Documentation 
form submitted 
on Blackboard – 









 Blackboard  Blackboard 
 
 90 
Course Grade:   
This is a 2-hour experience-based course graded “Credit/Fail”.  To receive credit for this 
course, the pharmacist-intern must satisfactorily complete all course requirements.  Failure 
to successfully complete any of the following course requirements will result in automatic 
failure of the entire course: 
 Completion of 80 experiential hours 
 Completion of APhA’s Delivering Medication Therapy Management Services in the 
Community certification course plus all required activities and documentation.  
Attendance at this course is required – no exceptions.  Failure to attend this course 
results in automatic failure of the course. 
o Successful completion of the self-study test 
o Successful completion of the pre-case workup 
o Completion and documentation of five CMR MTM cases 
o Statement of Completion 
 Completion of Public Health Project plus all required activities and documentation 
 Completion of Patient Safety exercises plus all required activities and 
documentation 
o Drug Utilization Review 
o Drug Information request 
o Medication Calendar 
 Completion of a minimum of two elective experiences plus all required activities and 
documentation 
 Reflections 
o MTM case 
o Public Health project 
o Patient Safety exercise 
o Elective exercise 
 Intern Evaluation Form  
o Must NOT receive 3 or more “2” ratings on the end of rotation evaluation 
o Must NOT receive a “1” rating on the end of rotation evaluation 
o A mid-rotation evaluation should be recorded on the pharmacist-intern’s 
evaluation form.  The practitioner-faculty member should discuss the 
pharmacist-intern’s overall performance with him/her, pointing out 
strengths and areas where improvement can be made.  Any indication that 
the pharmacist-intern may fail the course needs to be reported to the course 
coordinator as soon as possible. 
 Professional points – If the pharmacist-intern receives a deduction of 15 or more 
professional points during the course, he/she automatically fails the course.  The 
points are determined as follows: 
o Unscheduled absence – 10 points 
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o 15 minutes late for a shift – 3 points 
o No professional business casual attire, lab coat or UT name badge worn 
during your assigned shifts – 1 point 
o Designated deadlines on course timeline – 1 point for each day past deadline.  
These include the following: 
 All MTM cases – three separate deadlines throughout the course 
 Statement of Completion 
 All reflections 
 Medication Calendar 
 Failure of the course:  If a pharmacist-intern fails this course, the course must be 
repeated.  A delay in graduation is automatically implied since the course takes 




Deadlines for required documentation are on the timeline which is the last page of the 
syllabus.  All required documentation for the week must be submitted by 5pm that Friday. 
 
Schedules: 
Schedules will be determined by the pharmacist-intern and site preceptor.  The number of 
hours scheduled each week may vary depending on the pharmacist-intern, the preceptor 
and the practice site’s activities.  All efforts will be made to accommodate the schedules of 
involved entities.  Weekend and evening hours may be necessary to fulfill all course 
requirements, i.e. Saturday screenings, immunization clinics, etc.  Schedules for the 
following month need to be determined by the 22nd day of the month.  A week’s notice is 
required for any changes to the schedule and must be approved by the pharmacist-intern 
and site preceptor.  This notice must be done in the preferred form of the preceptor and 
may include email, phone call or other methods.   It is required that pharmacist-interns be 
present on all days of the scheduled rotation period.  Regular and prompt attendance 
mimics the actual working world. If you are unable to make your assigned shift at the last 
minute due to illness or other unforeseen circumstances, you must call the practice site as 
soon as you know you are unable to make your shift.  Failure to do so may result in a 
deduction of 10 professional points.  Studying for exams, double scheduling events during 
your assigned shifts, etc. are not considered unforeseen circumstances.  Holidays may be 
observed by the pharmacist-intern provided the preceptor approves.  Religious holidays 
may be observed according to University policy.  The pharmacist-intern must make up the 
hours missed during this time. 
 
The pharmacist-intern’s time should be divided up as follows: 
 Medication Therapy Management - ~70% 
 Public Health - ~15% 
 Patient Safety - ~5% 
 Elective Experience - ~10% 
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These are approximations and may vary slightly between sites. 
 
Hours Sheet: 
The Hours Sheet is designed to keep track of all hours worked each week plus any 
scheduled required documentation.  It is the pharmacist-intern’s responsibility to ensure 
this sheet is complete, accurate and current.  All entries need to be completed in ink.  At the 
end of the shift, the pharmacist-intern or preceptor must record the shift and hours 
completed and review any required documentation for that week.  If a preceptor feels that 
there is reason to believe that a pharmacist-intern may be misrepresenting his/her 
hours as recorded on the hour sheet, the Course Coordinator should be notified 
immediately.  This type of behavior constitutes academic dishonesty and will not be 
tolerated.  The penalty for falsification of hours is failure of the course. 
 
Standards of Conduct: 
 Pharmacist-interns are required to abide by the facility’s Health Information 
Portability and Accountability Act (HIPAA) policies.  You may be required to sign a 
temporary HIPAA form at your site. 
 Pharmacist-interns must abide by all laws and regulations pertaining to a 
pharmacist-intern as defined by the Texas Pharmacy Act and Rules.  Violation of 
these laws and regulations may jeopardize the pharmacist-intern’s privilege to 
become a registered pharmacist in Texas and may also result in failure of the course 
and dismissal from the College and/or the University. 
 Pharmacist-interns will be removed from a practice site for conduct deemed 
unprofessional by the preceptor and/or Student Affairs Office, or if the pharmacist-
intern’s actions endanger a patient’s health or welfare.  Removal from a practice site 
may result in failure of the course.  The core values of the University of Texas are 
learning, discovery, freedom, leadership, individual opportunity and responsibility.  
Each member of the university is expected to uphold these values through integrity, 
honesty, trust, fairness and respect towards peers and the community. 
 Professional demeanor and dress are expected and required throughout the course.  
The pharmacist-intern is representing the University of Texas College of Pharmacy 
and is expected to behave accordingly. 
 Honor code – You are expected to follow the University of Texas College of 




 Pharmacist-interns need to provide a binder to keep all records and documentation. 
 E-Mail – Email is recognized as an official mode of university correspondence; 
therefore, you are responsible for reading your email for university and course-
related information and announcements.  You are responsible for keeping the 
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university informed about changes to your email address.  You should check your 
email regularly and frequently.   Daily checking is recommended, but should be a 
minimum of twice weekly to stay current with university and course-related 
communications, some of which may be time-critical.  You can find UT Austin’s 
policies and instructions for updating your email address at 
http://www.utexas.edu/its/help/utmail/1564. 
 Transportation – The pharmacist-intern is responsible for his/her own 
transportation to and from any assigned practice site or class activity.  Prompt 
arrival is expected.  
 Dress Code - UT pharmacist-intern name badges, business casual dress and white 
jackets are to be worn at all times while fulfilling the course objectives.   Blue jeans 
and open-toed shoes are unacceptable dress even if the practice site allows it.  The 
Texas State Board of Pharmacy requires you to have your intern card in your 
possession at all times. 
 Cell phones are not to be used during the hours at your site.   
 Students with disabilities may request appropriate academic accommodations from 
the Division of Diversity and Community Engagement, Services for Students with 














PHR 287H Timeline – Fall 2011 
Note:  Spring 2012 timeline will be handed out at the end of the Fall 2011 
semester.  The MTM workshop will be conducted in early November. 
 
WEEK ACTIVITY COMPLETED 
Week One 
8/20 – 8/28 
 MTM Workshop – 8 hours 
 Orientation – 4 hours 




8/29 – 9/4 
 Hours worked at rotation site 
 Complete Start of Rotation self-evaluation 
 
Week Three 
9/5 – 9/11 
 Hours worked at rotation site  
Week Four 
9/12 – 9/18 
 Hours worked at rotation site  
Week Five 
9/19 – 9/25 
 Hours worked at rotation site  
Week Six 
9/26 – 10/2 
 Hours worked at rotation site 
 Public Health outline due – Show preceptor 
 
Week Seven 
10/3 – 10/9 
 Hours worked at rotation site  
Week Eight 
10/10 – 10/16 
 Hours worked at rotation site 
 Two CMR MTM cases due 
 Mid-rotation evaluation due 
 
Week Nine 
10/17 – 10/23 
 Hours worked at rotation site 
 MTM reflection due 
 
Week Ten 
10/24 – 10/30 
 Hours worked at rotation site 




10/31 – 11/6 
 Hours worked at rotation site  
Week Twelve 
11/7 – 11/13 
 Hours worked at rotation site 
 Two CMR MTM cases due 
 Elective reflection due 
 
Week Thirteen 
11/14 – 11/20 
 Hours worked at rotation site 
 Public Health reflection due 
 
Week Fourteen 
11/21 – 11/27 
 Hours worked at rotation site 
 One CMR MTM case due 




 Hours sheet and End-of-rotation evaluation 
due 








  Medication Therapy Review 
This review is based on the information available to the pharmacist as provided by the patient.  The MTR is to remain in the patient’s 
chart in the pharmacy and can be used as a reference when communicating with other healthcare providers. 
Patient Identifier:  Date of Birth:  Race: Sex: M / F 
Pharmacist/Student Intern:  Date Prepared: Patient Height: Patient Weight: 
Type of MTM visit:  Comprehensive Review      ⃝             Targeted Visit      ⃝ Blood Pressure: Blood Glucose: 
Primary Pharmacy and Phone Number:  
What questions does the patient have about his/her medications or disease states? 
Does the patient smoke or use tobacco products?  Y / N  If so, what type? 
For how long? How much per day? 
Does the patient drink alcoholic beverages?  Y / N If so, what type and how often? 
Does the patient drink caffeinated beverages?  Y / N If so, what type and how often? 
Medication Allergies and Adverse Drug Reactions (if known): 
Medical Conditions (Check all that apply): 
Alcoholism Breastfeeding Depression Heart failure Obesity 
Angina Cancer Diabetes High cholesterol Osteoporosis 
Arthritis Chronic headache GI disorder Hypertension Pregnancy 
Asthma Chronic pain Glaucoma Kidney disease Seizure disorder 
Bleeding disorder COPD Heart disease Liver disease Thyroid disease 
Other: 
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Medication Therapy Review  
Patient Identifier:  Date of Birth:  




Dose Directions Indication Physician Comments 
      
      
      
      
      
      
      
      
      
      
      
Over-the-Counter Medications: 
      
      
      
      
Herbal Supplements: 
      
      





Immunizations:  Influenza                        Y / N Pneumococcal         Y / N Tdap             Y / N 






































Always carry your medication record with you and show it to all your doctors, pharmacists and other healthcare providers.  Include all of your 
medications on this record:  prescription, non-prescription (OTC), vitamins, herbal products and other supplements.  
My Medication Record 
Patient Identifier:  Date of Birth:  
Pharmacist/Student Intern:  Date Prepared: 
Medication Take For Physician When Do I Take It? Special Instructions 
Name Dose     
      
      
      
      
      
      
      
      
      
      
      
      
      







































While intended to serve as a communication aid between patient (or other user) and health care provider, the MAP is not a substitute for obtaining health 
care advice or treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking 
any medication, or if you have or suspect you might have a health problem. 
My Medication-Related Action Plan 
Patient Identifier:  Date of Birth:  
Primary Physician:  Physician Phone:  
Primary Pharmacy:  Pharmacy Phone:  
Pharmacist/Student Intern:  Date prepared: 
The list below has important Action Steps to help you get the most from your medications. Follow the 
checklist to help you work with your pharmacist and physician(s) to manage your medications AND make 
notes of your actions next to each item on your list. 






Pharmacist Action Plan 
List the medication-related problems identified and the proposed interventions to resolve these problems 
Patient Identifier:  Date of Birth:  
Pharmacist/Student Intern:  Date Prepared: 
Medications or Conditions of Concern Medication Related Problem Intervention 
High / Mid / Low Priority:   
High / Mid / Low Priority:   
High / Mid / Low Priority:   
High / Mid / Low Priority:   
High / Mid / Low Priority:   
High / Mid / Low Priority:   
Recommendations for Follow-up: 
Outcome of Review: 
























Pharmacist Action Plan Progress Notes 
Patient Identifier:  Date of Birth:  
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Appendix A4 
Classification of Medication and Health-Related Problems and 
Types of Pharmacist Recommendations 
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Classification of Medication and Health-Related Problems and Types of Pharmacist 
Recommendations 
Medication-Related Problems Recommendation Type 
A 
prob 
Drug Product Selection A rec Drug-related 
      1 Drug needed, but not prescribed       1  Add drug 
      2 Prescribed drug not needed       2 Discontinue drug 
      3 Therapeutic duplication*       3 Change drug 
      4 Drug Efficacy*  4  Change dose 
      5 Drug Safety*       5 Change drug to over-the-counter (OTC) 
      6 Cost/Formulary Interchange*       6 Change dosage form 
B 
prob 
Regimen       7 Change route 
      1 Dose       8 Change schedule/duration 
      2 Schedule/Duration       9 Drug efficacy/safety lab monitoring 
      3 Route 10 Patient drug assistance program 









      1 Age*       1 Thyroid-stimulating hormone 
      2 Diseases or condition*   2 DEXA Scan 
      3 Drug*       3 Cholesterol screening 
      4 Food       4 Mammography/breast exam 
      5 Laboratory*       5 Sigmoidoscopy/colonoscopy 
D 
prob 
Adverse effects       6 Stool occult blood 
1 Side Effect       7 Depression screening 
2 Additive effects       8 Comprehensive metabolic profile 
      3 Allergy       9 Liver function tests 
      4 Toxicity     10 Tetanus vaccination 
E prob Patient product misuse     11 Pneumococcal vaccination 
      1 Underuse 12 Influenza vaccination 
      2 Overuse C rec Diabetic Care 
F prob Preventative care needs 1 Eye exam 
G 
prob 
Education 2 Hemoglobin A1C 
  3 Urine/creatinine ratio 
  4 Foot exam 
  D rec Education 
  1 Alcohol education 
  2 Smoking cessation education 
  3 Disease management education 
Prob. = problem; Rec. = recommendations 
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Appendix A 5 
Classification of students’ MTM Interventions (Medication-Related 
Problems (MRPs) and Needs, Actions-Related to Other Health Care 






















Classification of students’ MTM Interventions (Medication-Related Problems 
(MRPs) and Needs, Actions-Related to Other Health Care Providers, and Types of 
Recommendations)  
Medication and Health-Related Problems  
A 
prob. 
Drug Product Selection B 
prob. 
Regimen 
1 Over-the-counter (OTC) and herbal 
supplements  
1 Dose 
2 Drug needed, but not prescribed 2 Schedule/duration 
  3 Route 
  4 Dosage Form 
3 Prescribed drug not needed 5 Medication administration 
technique  
4 Therapeutic duplication 6 Route of administration  
5 Drug Efficacy 7 Other 
6 Drug Safety D 
prob. 
Adverse Effects and Use  
7 Cost/formulary Interchange 1 Additive effects 
C 
prob. 
Precaution/Interaction/Contraindication 2 Allergy 
1 Age 3 Toxicity 
2 Diseases or condition 4 Underuse 
3 Drug 5 Overuse 
4 Food F 
prob. 
Social Histories and Lifestyle 
Issues 
5 Alcohol 1 Smoking 
6 Laboratory  2 Excessive Alcohol 
consumption 
7 Pregnancy/Nursing 3 Lack of exercise  
E 
prob. 
Immunization  4 Obesity  
G 
prob. 
Lack of Understanding Drug 
Indication and Continuity of Care  
5 Poor diet  
1 Lack of understanding drug indication  6 Poor sleep  
2 Continuity of care  H 
prob. 
Disease Monitoring and 
Control 
  A Hypertension  
  1 Poor self –monitoring of blood 
pressure  
  2 Lack of blood pressure lab 
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  B  Diabetes  
  1 Poor self-monitoring of blood 
glucose  
  2 Lack A1C check 
  3 Lack of eye exam 
  4 Lack of foot inspection  
  C Dyslipidemia  
  1 Poor self-monitoring of lipid 
  2 Lack of foot inspection  
Action Related to Other Health Care Providers  
1 Contact health care provider  2 Ask patients to contact health 
care provider  
3 Counsel patients/caregiver  4 Education  
5 Referral to specialist    






1 Over-the-counter medication 
recommendation 
1 Health lab Monitoring 
1 Add drug 2 Cholesterol screening 
2 Discontinue drug 3 Depression screening 
3 Change drug 4 Mammography/breast exam 
4 Change dose 5 Pap smear 
5 Change drug to over-the-counter 
(OTC) 
6 Sigmoidoscopy/colonoscopy 
6 Change dosage form 7 Stool occult blood 
7 Change route D 
rec. 
Diabetic, Hypertensive and 
Dyslipidemic Monitoring and 
Control  
8 Change schedule/duration 1 Blood pressure 
monitoring/request blood 
pressure lab  
9 Drug efficacy/safety lab monitoring 2 Blood glucose 
monitoring/request A1c lab 
10 Request refill 3 Foot exam 
C 
rec. 
Immunizations 4 Eye exam 
1  Influenza vaccination 5 Lipids test 
2 Pneumococcal vaccination   
3 Zostavax/shingles vaccination   
4 Tetanus vaccination   
5 Hepatitis A vaccination   
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6 Hepatitis B vaccination   
7 Meningococcal vaccination   
E 
rec. 
Smoking and Alcohol Education   
1 Smoking cessation education   
2 Alcohol education   
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Mast Cell Stabilizers 
generic 





























































metronidazole vaginal     















































































All oral agents under this 
class are on the PML, if FDA 
approved.  
CARDIOVASCULAR 






































































Afeditab CR  
amlodipine 
Cartia XT  
Dilt XR 
diltiazem 




















Walgreens Health Initiatives 2010 Preferred Medication List  Medication Categories Guide  
Effective October 1, 2010  Page      
 
 



















































































































































































































































































amphetamine mixed salts 
dextroamphetamine/ 
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Promethazine VC with 
codeine 





















ACTOPLUS MET  
















Comfort Curve, Compact, 
Test Strips] 
NOVOFINE 
ONE TOUCH [Basic, 
FastTake, Suresoft, 
SureStep, Test Strips, 
Ultra, Ultra 2, Ultramini, 
Ultra Smart] 
SOFTCLIX LANCETS 
SOFT TOUCH LANCETS 
 










HUMALOG MIX 50/50 





































































































































Gastric Acid Secretion 
Reducers and 


























polyethylene glycol 3350  
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All medications used for the 
treatment of HIV are on the 

























































estradiol patch  























































































































DIFFERIN 0.1% LOTION 








METROGEL 1% KIT 








































ZOVIRAX 5% OINTMENT 
 
Corticosteroids 
Listed by potency: Group I is 





augmented 0.05% cream, 
ointment 
clobetasol 0.05% cream, 




betamethasone dipropionate  
0.05% cream, lotion, 
ointment 
desoximetasone  
0.25% cream, ointment 
fluocinonide 0.05% cream, 
gel, ointment, solution 




betamethasone valerate  
0.1% cream, lotion, 
ointment 
hydrocortisone valerate  
0.2%  ointment 
mometasone furoate  
0.1% cream, ointment, 
solution 
triamcinolone 0.025% 
cream, lotion, ointment 




desonide 0.05% cream, 
lotion, ointment 
fluocinolone 0.01% solution 
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Generic medications—listed in all lowercase letters or beginning with an Uppercase le tter—are on tier 1.  





































Urinary pH Modifiers  
generic 









All generic prenatal vitamins 



















































Coverage may vary by 
plans/pharmacies. Register 
on MyWHI.com and click on 



























Blood Cell Stimulators 
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